Document:

Amended and Restated Employment Agreement

 Exhibit 10.18 
 AMENDED AND RESTATED 
 EMPLOYMENT AGREEMENT

 This AGREEMENT, dated as of March 12, 2009 (the “Effective Date”), is between ZymoGenetics,
Inc., a Washington corporation (as supplemented by Section 13, the “Company”), and Douglas E. Williams (“Executive”). 
 RECITALS 
 A. The Company and Executive previously entered into the
Prior Agreement (as defined below) detailing compensation and benefit arrangements for Executive in the event of termination of Executive’s employment by the Company under certain circumstances. 
 B. The Company and Executive desire to update the terms of Executive’s employment. 
 Accordingly, in consideration of the promises and mutual covenants contained herein, the Company and Executive agree as follows: 

AGREEMENT 
 1. Certain
Definitions 
 1.1 “Accrued Obligations” has the meaning set forth in Section 7.1.

 1.2 “Annual Performance Bonus” has the meaning set forth in Section 5.5(b). 

1.3 “Cause” shall have the meaning set forth in Section 7.6. 
 1.4 “Change in Control” shall have the meaning set forth in Section 7.7. 
 1.5 “Change in Control Date” shall mean the first date during the Term (as defined in Section 4.1 on
which a Change in Control occurs. 
 1.6 “Change in Control Period” shall mean the two
(2) year period commencing on the Change in Control Date and ending on the second anniversary of such date. 
 1.7
“COBRA” shall mean the health care continuation requirements set forth in Code Section 4980B. 
 1.8 “Code” shall mean the Internal Revenue Code of 1986 and any regulations, rulings or other official guidance issued pursuant thereto, all as amended and in effect from time to time. 

 1.9 “Company Transaction” shall mean the consummation of
either (i) a merger or consolidation of the Company with or into any other company, entity or person or (ii) a sale, lease, exchange or other transfer of all or substantially all of the Company’s then outstanding securities or all or
substantially all of the Company’s assets in one transaction or a series of related transactions undertaken with a common purpose; provided, however, that a Company Transaction shall not include a Related Party Transaction. 
 1.10 “Compensation Committee” means the Compensation Committee of the Board of Directors. 
 1.11 “Fiscal Year” shall mean the fiscal year of the Company. 
 1.12 “Good Reason” shall have the meaning set forth in Section 7.5. 
 1.13 “Inventions Agreement” shall mean the Employee Inventions and Proprietary Information Agreement, dated
as of August 29, 2004, between the parties. 
 1.14 “Notice of Termination” shall have the
meaning set forth in Section 4.4. 
 1.15 “Prior Agreement” shall mean the Employment
Agreement, dated as of July 3, 2008, between the parties. 
 1.16 “Position” shall have the
meaning set forth in Section 2. 
 1.17 “Related Party Transaction” shall mean (i) a
merger or consolidation of the Company in which the holders of the outstanding voting securities of the Company immediately prior to the merger or consolidation hold at least a majority of the outstanding voting securities of the successor company
immediately after the merger or consolidation; (ii) a sale, lease, exchange or other transfer of the Company’s assets to a majority-owned subsidiary company; (iii) a transaction undertaken for the principal purpose of restructuring
the capital of the Company, including but not limited to, reincorporating the Company in a different jurisdiction or creating a holding company; or (iv) a corporate dissolution or liquidation. 
 1.18 “Successor Company” shall mean the surviving company, the successor company or its parent, as
applicable, in connection with a Company Transaction. 
 1.19 “Term” shall have the meaning set
forth in Section 4.1. 
 1.20 “Termination Date” shall have the meaning set forth in
Section 4.5. 
 2. Employment 
 The Company employs Executive and Executive accepts employment as Chief Executive Officer of the Company (the “Position”), unless terminated earlier as provided upon the terms and
conditions contained in this Agreement. Executive and the Company acknowledge that, except as otherwise may be provided under any other written agreement between Executive and the Company, the employment of Executive by the Company or its affiliated
companies is “at will” and may be terminated by either Executive or the Company or its affiliated companies at any time with or without cause. 
  

 -2- 

 3. Duties 
 During the Term, Executive shall serve the Company under the direction of the Board of Directors of the Company. Executive shall perform the duties of the Position faithfully, diligently and competently
and to the best of Executive’s ability, and, except as provided in this Section 3, shall devote Executive’s full business time to Executive’s employment. Executive shall perform such other duties as are assigned to Executive by
the Board of Directors of the Company. Executive may devote reasonable periods of time to (a) engaging in personal investment activities, (b) serving on the Board of Directors or Scientific Advisory Boards of other corporations with the
consent of the Compensation Committee of the Board of Directors, if such service would not otherwise be prohibited by Section 8 hereof (it is understood and agreed that Executive may continue to serve as a member of the Board of Directors of
Anadys Pharmaceuticals, Array Biopharma and Aerovance and as a member of the Scientific Advisory Board of Symphony Capital, and (c) engaging in charitable or community service activities, so long as none of the foregoing additional activities
materially interfere with Executive’s duties under this Agreement. 
 4. Term; Termination 
 4.1 Term 
 The “Term” of this Agreement initially shall be for a period of two (2) years from the Effective Date; provided, however, that this Agreement shall renew automatically for successive additional one (1) year
periods unless notice of non-renewal is given by either party to the other at least ninety (90) days prior to the end of the then current term; and provided further that if a Change in Control occurs during the Term, the Term shall
automatically extend at least for the duration of the Change in Control Period. 
 4.2 Termination by the Company or
Executive 
 The Company may terminate the employment of Executive, with or without Cause, at any time upon giving
“Notice of Termination” (as defined below). Executive may terminate Executive’s employment at any time, for any reason, upon giving Notice of Termination. 
 4.3 Automatic Termination 
 This Agreement and Executive’s employment
hereunder shall terminate automatically upon the death or Total Disability (as defined below) of Executive. The term “Total Disability” as used herein shall mean Executive’s inability to perform the duties set forth in
Section 3 hereof for a period or periods aggregating ninety (90) calendar days in any twelve (12) month period as a result of physical or mental illness, loss of legal capacity or any other cause beyond Executive’s control,
unless Executive is granted a leave of absence by the Board of Directors of the Company. Executive and the Company hereby acknowledge that Executive’s ability to perform the duties specified in Section 3 hereof is of the essence to this
Agreement. 
  

 -3- 

 4.4 Notice of Termination 
 The term “Notice of Termination” shall mean at least thirty (30) days’ written notice of termination, by
either party, of Executive’s employment and of this Agreement, during which period Executive’s employment and performance of services shall continue; provided, however, that the Company may, upon notice to Executive and without reducing
Executive’s compensation during such period, excuse Executive from any or all of Executive’s duties during such period. Such a reduction in duties shall not constitute Good Reason for termination so as to trigger termination payments in
accordance with Sections 7.2 or 7.3. 
 4.5 Termination Date 
 The effective date of the termination (the “Termination Date”) means (a) if Executive’s employment is
terminated by reason of death, at the end of the calendar month in which Executive’s death occurs, (b) if Executive’s employment is terminated by reason of Total Disability, immediately upon a determination by the Company of
Executive’s Total Disability, and (c) in all other cases, the later of (i) thirty (30) days after the date on which the Company or Executive, as applicable, receives the Notice of Termination from the other party or (ii) the
date specified in the Notice of Termination. 
 4.6 Survival 
 Sections 4, 7, 8, 9, 10, 14, 15, 16, 17, 18, 19, 20, 21, and 22 shall survive the termination of Executive’s employment and of this
Agreement. 
 5. Compensation and Benefits 
 5.1 Salary 
 During the Term, the Company shall pay to Executive as
compensation for the performance of Executive’s duties and obligations a salary of $550,000 per annum. This compensation is subject to annual review and adjustment, as appropriate in the judgment of the Company. The compensation payable
pursuant to this Section 5.1 shall be payable in equal semi-monthly installments on the last day of each such pay period. 
 5.2 Standard Benefits 
 Executive shall be enrolled and participate in any retirement, group insurance and other
fringe benefit plans and arrangements which are applicable to the similarly situated personnel of the Company and in effect from time to time, if Executive is eligible therefor, in each case in accordance with and subject to the provisions thereof.

 5.3 Stock Options 
 (a) Executive has been granted stock options under the Company’s 2001 Stock Incentive Plan which allows Executive to purchase shares of the Company’s common stock; and 
  

 -4- 

 (b) Executive shall be eligible to receive future periodic grants under the Company’s
stock incentive programs. 
 5.4 Other Benefits 
 Executive also shall receive the following executive perquisites for the duration of this contract: 
 (a) Company-paid term life insurance policy in the amount of $200,000; 
 (b) Company-paid use of either a laptop computer or personal computer, to be upgraded biennially at the time this contract is renewed;

 (c) Company-paid annual executive health physical, to be administered by a physician selected by the Company; and 

(d) Company-paid expenses for a residential phone and cellular phone. 
 5.5 Change in Control Period 
 As long as Executive remains employed by the Company or a Successor Company during the Change in Control Period, the Company agrees to pay or cause to be paid to Executive, and Executive agrees to accept
in exchange for the services rendered hereunder by Executive during the Change in Control Period, the following compensation: 
 (a) Executive shall receive an annual base salary at least equal to Executive’s annual base salary for the Fiscal Year in which the Change in Control Date occurs (as in effect immediately prior to the Change in Control Date).
Executive’s annual base salary shall be paid in substantially equal installments and at the same intervals as the salaries of other executives of the Company are paid. During the Change in Control Period, the Board of Directors, the
Compensation Committee or the Chief Executive Officer (as applicable) shall review Executive’s annual base salary at least annually and shall determine in good faith and consistent with any generally applicable Company policy any increases for
future years. 
 (b) In addition to an annual base salary, for each Fiscal Year ending during the Change in Control Period,
Executive shall be awarded an annual performance bonus (the “Annual Performance Bonus”) in cash at least equal to Executive’s target annual bonus for the Fiscal Year containing the Change in Control Date
or, if such target annual bonus has not been set as of the Change in Control Date, Executive’s target annual bonus for the immediately preceding Fiscal Year; provided, however, that except as provided in Section 7.3(b), an Annual
Performance Bonus shall be awarded for a Fiscal Year only if Executive is employed by the Company or a Successor Company on the last day of such Fiscal Year. Each Annual Performance Bonus shall be paid in the Fiscal Year following the Fiscal Year
for which the Annual Performance Bonus is awarded, but no later than the fifteenth (15th) day of the third (3rd) month of such subsequent Fiscal Year, unless Executive elects to defer the receipt of the Annual Performance Bonus in
accordance with the terms of the Company’s deferred compensation program. 
  

 -5- 

 (c) Executive shall be entitled to participate in, subject to and in accordance with the
eligibility and other terms and requirements thereof, such fringe benefit programs as generally are made available to other executives of the Company and its affiliated companies from time to time during the Change in Control Period, including,
without limitation, paid vacations; any stock purchase, savings or retirement plan, practice, policy or program; and welfare benefit plans, practices, policies or programs (including, without limitation, medical, prescription, dental, disability,
salary continuance, employee life, group life, accidental death and travel accident insurance plans or programs). 
 6. Expenses

 During the Term, all travel and other reasonable expenses incident to the rendering of service by
Executive hereunder shall be paid by the Company subject to Company policy. If such expenses are paid in the first instance by Executive, the Company shall reimburse Executive upon presentation of proper expense accounts and supporting
documentation. Reimbursement requests, along with supporting documentation, must be submitted within sixty (60) days after the date on which the expense for which reimbursement is being requested was incurred. Reimbursement shall be made no
later than the date that is two and one-half months (2 1/2) months after the end of the Fiscal Year in which the expense was incurred. 
 7. Termination Payments 

In the event of termination of the employment of Executive, all compensation and benefits set forth in this Agreement shall terminate
except as specifically provided in this Section 7. 
 7.1 Termination for Cause or Other than for Good Reason

 If during the Term Executive’s employment is terminated by the Company for Cause or by Executive for other than Good
Reason, this Agreement shall terminate without further obligation on the part of the Company to Executive, other than the Company’s obligation to pay (as provided in Section 7.8(a)) Executive the following accrued obligations (the
“Accrued Obligations”): 
 (a) Executive’s then current annual base salary through the Termination
Date; 
 (b) any Annual Performance Bonus to which Executive is entitled pursuant to Section 5.5(b) (i.e., a bonus paid for
a Fiscal Year ending during the Change in Control Period if Executive was employed by the Company or a Successor Company on the last day of such Fiscal Year); 
 (c) any compensation previously deferred by Executive (together with accrued interest or earnings thereon, if any); and 
 (d) any accrued vacation pay that would be payable under the Company’s standard policy; 
 in each case, to the extent not theretofore paid. 
  

 -6- 

 7.2 Termination Other than for Cause or for Good Reason NOT During Change in Control
Period 
 Subject to Section 9, if at any time during the Term, except during the Change in Control Period, the Company
terminates Executive’s employment other than for Cause or Executive terminates Executive’s employment for Good Reason, Executive shall be entitled to: 
 (a) any Accrued Obligations to the extent theretofore unpaid; 
 (b) if, as a
result of the termination of Executive’s employment, Executive and Executive’s spouse and dependent children are eligible for and timely (and properly) elect COBRA continuation coverage under the Company’s group health plan(s), the
Company shall pay the premium for such coverage for a period of twelve (12) months following the Termination Date, until Executive becomes covered under a comparable group health plan, or until Executive is no longer entitled to COBRA
continuation coverage under the Company’s group health plan(s), whichever period is the shortest, but only to the extent that the Company would have paid such premiums had Executive remained employed by the Company; 
 (c) severance payments equal, in the aggregate, to one (1) times Executive’s annual base salary as of the date of the Notice of
Termination, payable as provided in Section 7.8(b). 
 7.3 Termination Other than for Cause or for Good Reason During
Change in Control Period 
 Subject to Section 9, if during the Change in Control Period, the Company terminates
Executive’s employment other than for Cause or Executive terminates Executive’s employment for Good Reason, Executive shall be entitled to: 
 (a) any Accrued Obligations to the extent theretofore unpaid; 
 (b) a bonus for
the Fiscal Year that contains the Termination Date, which bonus shall not be less than the Annual Performance Bonus multiplied by a fraction, the numerator of which is the number of days in such Fiscal Year up to and including the Termination Date
and the denominator of which is three hundred sixty-five (365), payable as provided in Section 7.8(c). This Section 7.3(b) shall not apply if Executive is entitled to an Annual Performance Bonus pursuant to Section 5.5(b) for the
Fiscal Year containing the Termination Date; 
 (c) if, as a result of the termination of Executive’s employment, Executive
and Executive’s spouse and dependent children are eligible for and timely (and properly) elect COBRA continuation coverage under the Company’s group health plan(s) pursuant to COBRA, the Company shall pay the premium for such coverage for
a period of twelve (12) months following the Termination Date, until Executive becomes covered under a comparable group health plan, or until Executive is no longer entitled to COBRA continuation coverage under the Company’s group health
plan(s), whichever period is the shortest, but only to the extent that the Company would have paid such premiums had Executive remained employed by the Company; 
 (d) immediate vesting of all outstanding stock options previously granted to Executive by the Company; 
  

 -7- 

 (e) an amount as severance pay equal to the sum of (i) two (2) times the Annual
Performance Bonus and (ii) two (2) times Executive’s annual base salary as of the date of the Notice of Termination, payable as provided in Section 7.8(c). 
 7.4 Termination as a Result of Death or Total Disability 
 In the event of termination of Executive’s employment pursuant to Section 4.3, Executive or Executive’s estate shall be paid
the compensation set forth in Section 7.1. 
 7.5 Good Reason 
 (a) “Good Reason” shall mean the occurrence of any of the following conditions, without the consent of Executive:

  

	 	(i)	a demotion or other material reduction in the nature or status of Executive’s responsibilities; provided, however, that a change in the person or office to which
Executive reports, without a corresponding reduction in duties, status and responsibilities, shall not constitute “good reason;” 

  

	 	(ii)	a reduction in the Executive’s annual base salary; 

  

	 	(iii)	requirement by a Successor Company that the Executive relocate his principal place of employment to a location that is more than fifty (50) miles from the
principal place of employment where Executive was employed; 

  

	 	(iv)	the failure of Company to obtain a satisfactory agreement from any Successor Company to assume and perform the obligations under this Agreement within thirty
(30) calendar days after the consummation of a merger, consolidation, sale or similar transaction; 

  

	 	(v)	following a Change in Control (as defined in Section 7.6 ), the Executive ceases to hold the positions of Chief Executive Officer of the parent or combined entity
resulting from such Change in Control; or 

  

	 	(vi)	even if there is no Change in Control, but the Company enters into a merger, partnership or similar transaction, which results in a person other than the Executive
becoming Chief Executive Officer of the new combined entity. 

 (b) Notwithstanding any provision in this
Agreement to the contrary, termination of employment by Executive will not be for Good Reason unless (i) Executive notifies the Company or the Successor Company in writing of the existence of the condition which Executive believes constitutes
Good Reason within ninety (90) days of the initial existence of such condition (which notice specifically identifies such condition), (ii) the Company or the Successor Company fails to remedy such condition within thirty (30) days
after the date on which it receives such notice (the “Remedial Period”), and (iii) Executive actually terminates employment within thirty (30) days after the expiration of the Remedial Period and before the Company
or the Successor Company remedies such condition. If Executive terminates employment before the expiration of the Remedial Period or after the Company or the Successor Company remedies the condition (even if after the end of the Remedial Period),
then Executive’s termination will not be considered to be for Good Reason. Executive may combine the notice required by this Section 7.5(b) with the Notice of Termination. 
  

 -8- 

 7.6 Cause 
 Wherever reference is made in this Agreement to termination being with or without Cause, “Cause” shall include,
without limitation, the occurrence of one or more of the following events: 
 (a) willful misconduct or insubordination in the
performance of Executive’s duties or other knowing and material violation of the Company’s policies and procedures in effect from time to time which results in a material adverse effect on the Company; 
 (b) willful actions in bad faith (or intentional failures to act) by Executive with respect to the Company that materially impair the
Company’s business, goodwill or reputation; 
 (c) current abuse by Executive of controlled substances; deception, fraud,
misrepresentation or dishonesty by Executive; or any incident materially compromising Executive’s reputation or ability to represent the Company with investors, customers or the public; 
 (d) conviction of Executive of a felony involving an act of dishonesty, moral turpitude, deceit or fraud, or the commission or omission of
acts that could reasonably be expected to result in such a conviction; or 
 (e) any material violation by Executive of this
Agreement or the Inventions Agreement with the Company, subject to the notice and opportunity-to-cure requirements of Section 11 hereof. 
 7.7 Change in Control 
 As used herein, a “Change in
Control” shall mean any of the following events or occurrences, provided such event or occurrence also constitutes a change in ownership or effective control of the Company, or in the ownership of a substantial portion of the
Company’s assets, within the meaning of Code Section 409A(a)(2)(A)(v): 
 (a) The acquisition by any individual,
entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) (a “Person”), either directly or indirectly through one
or more affiliated entities (collectively “Series B Purchasers”), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 50% or more of either (x) the then outstanding shares of
common stock of the Company (the “Outstanding Company Common Stock”) or (y) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the
“Outstanding Company Voting Securities”); provided, however, that for purposes of this Section 7.7(a), the following acquisitions shall not constitute a Change in Control: (A) any acquisition by any employee benefit
plan (or related trust) sponsored or maintained by the Company or (B) any acquisition by any corporation pursuant to a transaction which complies with clauses (A), (B) and (C) of Section 7.7(b); or 
  

 -9- 

 (b) Consummation of a reorganization, merger or consolidation or sale or other disposition
of all or substantially all of the assets of the Company (a “Business Combination”), in each case, unless, following such Business Combination: (A) all or substantially all of the individuals and entities who were the
beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than fifty percent (50%) of,
respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such
Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries), (B) no
Person (excluding (1) any one or more Series B Purchasers, (2) any corporation resulting from such Business Combination, or (3) any employee benefit plan (or related trust) of the Company or such corporation resulting from such
Business Combination) beneficially owns, directly or indirectly, fifty percent (50%) or more of, respectively, the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power
of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination and (C) at least a majority of the members of the Board of Directors of the corporation resulting
from such Business Combination were members of the incumbent Board of Directors of the Company at the time of the execution of the initial agreement, or of the action of the Board of Directors, providing for such Business Combination; 
 (c) Approval by the shareholders of the Company of a complete liquidation or dissolution of the Company; or 
 (d) A “Board Change” that, for purposes of this Agreement, shall have occurred if, during any twelve (12) month
period, a majority of the members of the Company’s Board of Directors is replaced by directors whose appointment or election is not endorsed by a majority of the members of the Company’s Board of Directors before the date of the
appointment or election. 
 7.8 Payment Schedule 
 (a) All payments of Accrued Obligations, or any portion thereof payable pursuant to this Section 7, other than deferred compensation,
shall be made to Executive within ten (10) working days of the Termination Date. Deferred compensation pursuant to Section 7.1(b) shall be payable pursuant to the terms of the deferred compensation plan, program or arrangement pursuant to
which it was deferred. 
 (b) Subject to Section 21, the payments payable to Executive pursuant to Section 7.2(c)
shall be paid to Executive in equal installments on each of the Company’s semi-monthly pay days during the twelve (12) month period immediately following the Termination Date, subject to the following: 
  

	 	(i)	If Code Section 409A does not apply to the payments that would be made during the first sixty (60) days following the Termination Date, then payments shall
begin as of the first semi-monthly pay day following the date on which Executive’s release under Section 9(a) becomes effective. The initial payment shall include any such installments that would have been paid prior to such pay day had
payments commenced on the first semi-monthly pay day following the Termination Date; and 

  

 -10- 

	 	(ii)	If Code Section 409A applies to the payments that would be made during the first sixty (60) days following the Termination Date, then payments shall begin as
of the first semi-monthly pay day following the sixtieth (60th) day after the Termination Date. The initial payment shall include any such installments that would have been paid prior to such pay day had payments commenced on the first
semi-monthly pay day following the Termination Date. 

 For purposes of Code Section 409A, each installment payable pursuant
to Section 7.2(c) and this Section 7.8(b) shall be treated as a separate payment. 
 (c) Subject to Section 21,
any payments payable to Executive pursuant to Sections 7.3(b) and (e) shall be made to Executive in a lump sum on the first business day following the date on which Executive’s release under Section 9(a) becomes effective, unless
any portion of such payments is subject to Code Section 409A, in which case they shall be made on the first business day that is at least sixty-one (61) days following the Termination Date. 
 7.9 Parachute Payments. 
 (a) Notwithstanding any other provision in this Agreement, in the event any payments or benefits Executive receives or would become entitled to receive from the Company, any person whose actions result in
a Change in Control or any person affiliated with the Company or such person (in the aggregate, the “Payments”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code,
and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code or any similar or successor provision (the “Excise Tax”), then the amount of the Payments shall be equal to either
(x) the largest portion of the Payments that would result in no portion of the Payments being subject to the Excise Tax (the “Reduced Amount”), or (y) the full amount of the Payments, whichever of the foregoing
amounts, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest marginal rate applicable to individuals in the year in which the Payments are to be made),
results in Executive’s receipt, on an after-tax basis, of the greatest amount of the Payments notwithstanding that all or some portion of the Payments may be subject to the Excise Tax. If a reduction in the Payments is required so that the
amount of the Payments equals the Reduced Amount, the Payments shall be reduced in the following order: (1) reduction of cash Payments otherwise payable to Executive that are exempt from Section 409A of the Code; (2) cancellation of
accelerated vesting of equity awards (other than stock options) that are exempt from Section 409A of the Code; (3) cancellation of accelerated vesting of stock options that are exempt from Section 409A of the Code; (4) reduction
of any other payments and benefits otherwise payable to Executive that are exempt from Section 409A of the Code; and (5) reduction of any other

  

 -11- 

 
benefits and payments otherwise payable to Executive on a pro-rata basis or such other manner that complies with Section 409A of the Code, as determined by the Company. If acceleration of
vesting of Executive’s stock options or other equity awards is to be reduced pursuant to clauses (2) or (3) of the immediately preceding sentence, such acceleration of vesting shall be cancelled by first canceling such acceleration
for the vesting installment that will vest last and continuing by canceling as a first priority such acceleration for the vesting installment with the latest vesting. 
 (b) All computations and determinations called for by this Section 7.9 shall be made and reported in writing to the Company and Executive by an independent accounting firm or independent tax counsel
appointed by the Company (the “Tax Advisor”), and all such computations and determinations shall be conclusive and binding on the Company and Executive. For purposes of such calculations and determinations, the Tax
Advisor may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive shall furnish to the Tax Advisor such information and documents as the Tax Advisor may reasonably
request in order to make their required calculations and determinations. The Company shall bear all fees and expenses charged by the Tax Advisor in connection with its services. 
 7.10 Withholding 
 The Company may deduct from any amounts payable under this Agreement, any amounts that it is required by law to withhold, including, without limitation, social security taxes, federal and state income taxes, and state disability insurance;
provided, however, that any and all such obligations shall be Executive’s responsibility. 
 8. Non-competition and Non-solicitation

 8.1 Non-competition 
 During the Term and for a period of twelve (12) months after the Termination Date, Executive shall not directly or indirectly work or otherwise engage in research, development, manufacture, sale or
distribution of any product, method or matter: 
 (a) For any business, whose commercial efforts are in competition with the
products manufactured or marketed by the Company during Executive’s employment with the Company or under research or development by the Company during Executive’s employment with the Company (and on which the Company has expended at least
$500,000); or 
 (b) For any research institution whose research efforts pertain to the same products manufactured or marketed
by the Company during Executive’s employment with the Company or under research or development by the Company during Executive’s employment with the Company (and on which the Company has expended at least $500,000), unless Executive is not
involved in any manner in the design, conduct or supervision of such research efforts, or unless such research is being conducted solely for scientific and not for commercial purposes. 
  

 -12- 

 Executive shall be deemed to be engaged in a business if such business is carried on by
partnership in which Executive is a general or limited partner, consultant or employee, or a corporation or association of which Executive is a shareholder, officer, director, employee, member, consultant or agent; provided, that nothing herein
shall prevent the purchase or ownership by Executive of shares of less than one percent (1%) of the outstanding shares in a publicly or privately held corporation. 
 Said twelve (12) months’ period shall commence on the day on which Executive actually leaves Executive’s employment with the Company, even if this date is prior to the expiration of any
given Notice of Termination. 
 8.2 Waiver of Non-competition 
 The Company’s Board of Directors may, at its own discretion, by express or written consent, release Executive from the restriction in
Section 8.1. 
 8.3 Non-solicitation 
 During the Term and for a period of one (1) year after the Termination Date, Executive shall not personally or through others (a) recruit, solicit or induce in any way any employee, advisor or
consultant of the Company to terminate his, her or its relationship with the Company or to engage in activities competitive with the Company, (b) hire or attempt to hire for any purpose, as an employee, agent, consultant or contractor, any
person who then is an employee of the Company, or (c) solicit, induce or encourage in any way any customers (that Executive sold to, serviced or solicited on behalf of the Company), strategic partners, contractors, suppliers, or vendors to
terminate or reduce their relationships with the Company or to refrain from entering or expanding any business or relationship with the Company. 
 9. General Release of Claims and Compliance by Executive 
 (a) As a condition to the payments and benefits
contemplated by Section 7 (other than Accrued Obligations), Executive must execute (and not later revoke) a general release and waiver of claims against the Company in a form satisfactory to the Company in its sole discretion. By way of example
and not limitation, the general release and waiver of claims will include any claims for wages, bonuses, employment benefits, or damages of any kind whatsoever, arising out of any contracts, express or implied, any covenant of good faith and fair
dealing, express or implied, any theory of wrongful discharge, any legal restriction on the Company’s right to terminate employment, or any federal, state or other governmental statute or ordinance, including, without limitation, Title VII of
the Civil Rights Act of 1964, the federal Age Discrimination in Employment Act, the Americans with Disabilities Act, the Family and Medical Leave Act, the Washington Law Against Discrimination, or any other legal limitation on the employment
relationship. Such release and waiver must be executed and effective (and the applicable revocation period must have expired without the release and waiver being revoked) not more than sixty (60) days after the Termination Date or Executive
shall not be entitled to any such payments or benefits. 
 (b) In addition, the payments and benefits contemplated by
Section 7 (other than Accrued Obligations) are expressly contingent upon Executive’s full compliance with Executive’s obligations towards the Company, including, without limitation, the terms of the Inventions Agreement and the
non-competition provision of Section 8.1. In the event Executive materially

  

 -13- 

 
breaches the Inventions Agreement or Section 8.1, Executive’s right to any payments or benefits under Section 7 (including those that have already been made or provided), other
than Accrued Obligations, shall be forfeited and extinguished, regardless of whether the Company takes legal action or otherwise tries to enforce its rights. In such event, the Company shall cease payments, and Executive shall immediately return to
the Company any payments already made. The Company reserves all rights it may have under contract or law to relief or damages in addition to termination of the above-described payments. 
 10. Return of Materials 
 All documents, records, notebooks, notes,
memoranda, drawings or other documents made or compiled by Executive at any time while employed by the Company, or in Executive’s possession, including any and all copies thereof, shall be the property of the Company and shall be held by
Executive in trust and solely for the benefit of the Company, and shall be delivered to the Company by Executive upon termination of employment or at any other time upon request by the Company. 
 11. Notice and Cure of Breach 
 Except as provided otherwise in Section 7.5(b), whenever a breach of this Agreement by either party is relied upon as justification for any action taken by the other party pursuant to any provision of this Agreement, other than clauses
(a), (b), or (c) of Section 7.6, before such action is taken, the party asserting the breach of this Agreement shall give the other party at least twenty (20) days’ prior written notice of the existence and the nature of such
breach before taking further action hereunder and shall give the party purportedly in breach of this Agreement the opportunity to correct such breach during the twenty (20) day period. 
 12. No Violation of Other Agreements 
 In order to induce the Company to enter into this Agreement, Executive represents and warrants to the Company that neither the execution nor the performance of this Agreement by Executive shall violate or
conflict in any way with any other agreement or obligations by which Executive may be bound. 
 13. Rights of Assignment or Delegation 

 This Agreement is personal to Executive and shall not be assignable by Executive. The Company may assign its rights hereunder
to (a) any corporation resulting from any merger, consolidation, or other reorganization to which the Company is a party or (b) any corporation, partnership, association, or other person to which the Company may transfer all or
substantially all of the assets in business of the Company existing at such time. As used in this Agreement, “Company” shall mean ZymoGenetics, Inc. and any successor to its business and/or assets that assumes and agrees to
perform this Agreement by operation of law, or otherwise. All the terms and provisions of this Agreement shall be binding upon and shall inure to the benefit and be enforceable by the parties hereto and their respective heirs, legal or personal
representatives, successors and permitted assigns. 
  

 -14- 

 14. Waiver 
 No delay or failure by any party in exercising, protecting or enforcing any of its rights, titles, interests, or remedies hereunder and no course of dealing or performance with respect thereto, shall
constitute a waiver. The express waiver by a party of any right, title, interest, or remedy in a particular instance or circumstance shall not constitute a waiver in any other instance or circumstance. All rights and remedies shall be cumulative and
not exclusive of any rights or remedies. 
 15. Arbitration 
 Any controversies or claims arising out of or relating to this Agreement shall be settled finally and fully by arbitration in Seattle, Washington in accordance with the Employment Arbitration Rules of the
American Arbitration Association then in effect (the “AAA Rules”), conducted by one arbitrator, mutually agreed upon by the Company and Executive or chosen in accordance with the AAA Rules, except the parties thereto shall have any right
to discovery that would be permitted by the Federal Rules of Civil Procedure for a period of ninety (90) days following the commencement of such arbitration and the arbitrator shall resolve any dispute which arises in connection with such
discovery. The prevailing parties shall be entitled to costs, expenses, reasonable attorneys’ fees, and judgment upon the award rendered by the arbitrator. The award may be entered in any court having jurisdiction. To the extent necessary to
prevent Executive from being subject to any additional tax pursuant to Code Section 409A(a)(1)(B), any amounts payable to Executive pursuant to this paragraph shall be paid in no event later than the year following the year during which such
costs and fees were incurred. 
 16. Amendments in Writing 
 No amendment, modification, waiver, termination or discharge of any provision of this Agreement, nor consent to any departure by either party, shall in any event be effective unless the same shall be in
writing, specifically identifying this Agreement and the provision intended to be amended, modified, waived, terminated, or discharged and assigned by the Company and Executive. Each such amendment, modification, waiver, termination, or discharge
shall be effective only in the specific instance and for the specific purpose for which given. No provision of this Agreement shall be varied, contradicted, or explained by any oral agreement, course of dealing or performance or any other matter not
set forth in agreement in writing and signed by the Company and Executive. 
 17. Notices 
 Any notice required or desired to be given hereunder shall be in writing and shall be deemed sufficiently given when delivered or when mailed
by first class certified or registered mail, postage prepaid, to the party for whom intended at the following address: 
 To the
Company: 
 Chairman of the Board 
 ZymoGenetics, Inc. 
 1201 Eastlake Avenue East 
 Seattle, WA 98102 
  

 -15- 

 To Executive: 
 Douglas E. Williams 
 21800 Nootka Road 
 Woodway, WA 98020 
 or to such other address, as to either party, as such party shall from time to time designate by like notice to the other. 
 18. Entire Agreement 
 This
Agreement supersedes and replaces the Prior Agreement and constitutes the entire agreement between the Company and Executive with respect to the subject matter hereof, and all prior or contemporaneous oral or written communications, understandings
or agreements between the Company and Executive with respect to such subject matter, are hereby superseded and nullified in their entireties, except that the Inventions Agreement shall continue in full force and effect. 
 19. Governing Law 
 This
Agreement is made under and shall be governed by and construed in accordance with the laws of the State of Washington (without regard to any rules governing conflict of laws), except to the extent preempted by Federal law. 
 20. Severability 
 If any
provision of this Agreement shall be held invalid, illegal or unenforceable in any jurisdiction, for any reason, including without limitation, the duration of such provision, its geographical scope or the extent of the activities prohibited or
required by it, then, to the full extent permitted by law (a) all other provisions hereof shall remain in full force and effect and such provision shall be liberally construed in order to carry out the intent of the parties as nearly as may be
possible, (b) such invalidity, illegality, or unenforceability shall not affect the validity, legality or enforceability of any other provision, and (c) any court or arbitrator having jurisdiction thereover shall have the power to reform
such provision to the extent necessary for such provision to be enforceable under applicable law. 
 21. 409A Interpretation Provision 

 The parties intend that this Agreement and the benefits provided hereunder be exempt from the requirements of
Code Section 409A to the maximum extent possible, whether pursuant to the short-term deferral exception described in Treasury Regulation Section 1.409A-1(b)(4), the involuntary separation pay plan exception described in Treasury Regulation
Section 1.409A-1(b)(9)(iii), or otherwise. To the extent Code Section 409A is applicable to this Agreement, the parties intend that this Agreement comply with the deferral, payout and other limitations and restrictions imposed under Code
Section 409A. Notwithstanding any other provision of this Agreement to the contrary, this Agreement shall be interpreted, operated and administered in a manner consistent with such intentions. Without limiting the generality of the foregoing,
and notwithstanding any other provision of this Agreement to the contrary, with respect to any

  

 -16- 

 
payments and benefits under this Agreement to which Code Section 409A applies, all references in this Agreement to the termination of Executive’s employment are intended to mean
Executive’s “separation from service,” within the meaning of Code Section 409A(a)(2)(A)(i). In addition, if Executive is a “specified employee,” within the meaning of Code Section 409A, then to the extent necessary
to avoid subjecting Executive to the imposition of any additional tax under Code Section 409A, amounts that would otherwise be payable under this Agreement during the six (6) month period immediately following Executive’s
“separation from service,” within the meaning of Code Section 409A(a)(2)(A)(i), shall not be paid to Executive during such period, but shall instead be accumulated and paid to Executive (or, in the event of Executive’s death,
Executive’s estate) in a lump sum on the first business day after the earlier of the date that is six (6) months following Executive’s separation from service or Executive’s death. If the Company or Executive determines that any
provision of this Agreement is or might be inconsistent with the requirements of Code Section 409A, the parties shall attempt in good faith to agree on such amendments to this Agreement as may be necessary or appropriate to avoid subjecting
Executive to the imposition of any additional tax under Code Section 409A. Notwithstanding the foregoing, no provision of this Agreement shall be interpreted or construed to transfer any liability for failure to comply with Code
Section 409A from Executive or any other individual to the Company or any of its affiliates. 
 22. Multiple Copies 
 This Agreement may be executed in two (2) or more counterparts of like tenor and effect, each of which shall be deemed an original but
all of which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, the parties have executed and entered
into this Agreement as of the Effective Date. 
  

			
	 ZYMOGENETICS, INC.

		
	 By:
	 	 /s/ Bruce L.A. Carter

		 	Bruce L.A. Carter, Ph.D.
		 	Chairman

  

	
	 EXECUTIVE

	
	 /s/ Douglas E. Williams

	Douglas E. Williams

  

 -17-Third Amended and Restated License Agreement

 Exhibit 10.37 
  

					
		 		 	 *  Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the
Securities Exchange Act of 1934, as amended.

 THIRD RESTATED LICENSE AGREEMENT 
 FOR IL-21 EMBODIMENTS 
 by and between 
 ZymoGenetics, Inc., 
 and 
 Novo Nordisk A/S 
 Effective Date: December 3, 2009 

 CONTENTS 
  

							
	ARTICLE ONE Definitions and Terminology	  	1
	 1.1
	 	Definitions	  	1
	 1.2
	 	Terminology	  	11
		
	ARTICLE TWO License	  	11
	 2.1
	 	License Grant	  	11
	 2.2
	 	Nonexclusive License Grant – IL-21 Protein	  	11
	 2.3
	 	Sublicensing by NN	  	11
	 2.4
	 	ZGEN Reservation of Rights	  	12
	 2.5
	 	Transition Plan	  	12
	 2.6
	 	Development	  	12
	 2.7
	 	Commercialization	  	13
	 2.8
	 	[*] Technology	  	13
		
	ARTICLE THREE Upfront and Milestone Fees	  	14
	 3.1
	 	Execution Fee	  	14
	 3.2
	 	Milestone Fees	  	14
	 3.3
	 	Milestone Fees under [*] Agreement	  	15
		
	ARTICLE FOUR Royalties	  	15
	 4.1
	 	Patent Products	  	15
	 4.2
	 	Know-How Products	  	16
	 4.3
	 	Not Additive; Aggregation	  	16
	 4.4
	 	Third Party Agreements	  	16
		 	 4.4.1
	 	General	  	16
		 	 4.4.2
	 	Royalties under [*] Agreement	  	17
	 4.5
	 	Generic Products	  	17
	 4.6
	 	Additive Offsets; Minimum Royalties	  	17
	 4.7
	 	Payments and Reports	  	18
	 4.8
	 	Taxation of Payments	  	18
	 4.9
	 	Currency Blockage	  	19
		
	ARTICLE FIVE Co-Funding Phase III Clinical Development and USA Co-Promotion	  	19
	 5.1
	 	Election to Co-Fund	  	19
	 5.2
	 	Procedure	  	19
	 5.3
	 	Consequences of Election to Co-Fund	  	19
		 	 5.3.1
	 	Cost Sharing	  	19
		 	 5.3.2
	 	Royalties on Net Sales in the USA	  	19
		 	 5.3.3
	 	ZGEN’s Right to Co-Promote in USA	  	20
	 5.4
	 	Phase III Costs	  	20
		 	 5.4.1
	 	Cost Sharing of Phase III Costs	  	20
		 	 5.4.2
	 	Accounting and Reconciliation	  	20
	 5.5
	 	Co-Promotion in USA	  	22

  

 -i- 
 * Confidential Treatment Requested. 

							
		 	5.5.1	 	USA Co-Promotion Agreement	  	22
		 	5.5.2	 	Right to Co-Promote	  	22
	 5.6
	 	ZGEN’s Right to Opt Out of Co-Funding	  	23
		
	ARTICLE SIX Relationship Management	  	23
	 6.1
	 	Joint Executive Committee	  	23
		 	6.1.1	 	Formation; Composition; Decisions	  	23
		 	6.1.2	 	Role and Responsibilities	  	24
		 	6.1.3	 	Meetings and Communications	  	24
	 6.2
	 	Development and Commercialization Plan	  	24
	 6.3
	 	Alliance Managers	  	25
		 	6.3.1	 	Appointment	  	25
		 	6.3.2	 	Responsibilities	  	25
	 6.4
	 	Finance Contacts	  	26
		
	ARTICLE SEVEN Confidentiality	  	26
	 7.1
	 	Confidential Information	  	26
	 7.2
	 	Confidentiality Obligation	  	27
	 7.3
	 	Release from Confidentiality Obligation	  	27
		
	ARTICLE EIGHT Indemnification	  	28
	 8.1
	 	Personal Injury or Property Damage	  	28
	 8.2
	 	Insurance	  	28
		
	ARTICLE NINE Patents	  	29
	 9.1
	 	Prosecution	  	29
	 9.2
	 	Patent Term Extension	  	30
	 9.3
	 	Notice of Infringement and Conference	  	31
	 9.4
	 	ZGEN Has First Right	  	31
	 9.5
	 	NN Has Secondary Right	  	32
	 9.6
	 	Settlement	  	33
	 9.7
	 	Patent Contacts	  	33
	 9.8
	 	Cooperation	  	33
	 9.9
	 	Affiliates, Commercialization Partners and Sublicensees	  	34
	 9.10
	 	Filing, Prosecution, Maintenance of Cell Line Patents and Construction Strain Patents	  	34
	 9.11
	 	Filing, Prosecution, Maintenance of Patents and Patent Applications arising from Work Performed pursuant to Annual Plan or Long Range Plan	  	34
		
	ARTICLE TEN Term and Termination	  	34
	 10.1
	 	Term and Expiration	  	34
	 10.2
	 	Termination by NN for Convenience	  	34
	 10.3
	 	Safety Reasons	  	35
	 10.4
	 	Insolvency	  	35
	 10.5
	 	Breach	  	35

  

 -ii- 

					
	 10.6
	 	Termination of License With Respect to Contested Patent Rights	  	36
	 10.7
	 	Effect of Expiration or Termination	  	36
	 10.8
	 	Survival of Obligations under Second Restated License Agreement	  	36
	 10.9
	 	Return of Project Following Termination	  	36
		
	 ARTICLE ELEVEN Representations and Warranties
	  	37
	 11.1
	 	Representations, Warranties and Covenants of NN	  	37
	 11.2
	 	Representations, Warranties and Covenants of ZGEN	  	38
	 11.3
	 	Warranty Disclaimer	  	39
	 11.4
	 	Limited Liability	  	39
		
	 ARTICLE TWELVE Miscellaneous
	  	39
	 12.1
	 	Assignment	  	39
	 12.2
	 	Relationship between the Parties	  	40
	 12.3
	 	Public Announcements	  	40
	 12.4
	 	Use of Names, Trade Names and Trademarks	  	41
	 12.5
	 	Force Majeure	  	41
	 12.6
	 	Governing Law	  	41
	 12.7
	 	Waiver of Remedies	  	41
	 12.8
	 	Entire Agreement	  	41
	 12.9
	 	Notices	  	42
	 12.10
	 	Severability	  	42
	 12.11
	 	Headings	  	42
	 12.12
	 	Review of Agreement	  	42
	 12.13
	 	Compliance with Laws; Export Regulations	  	43
	 12.14
	 	[*]	  	43
	 12.15
	 	Counterparts	  	43

  

 -iii- 
 * Confidential Treatment Requested. 

			
	LIST OF SCHEDULES AND APPENDICES
		
	 Schedule 1
	 	Illustrative List of Items to be Transferred in Accordance with Section 2.5 – Transition Plan
	 Schedule 2
	 	Press Release
	 Schedule 3
	 	Description of Certain Sales Incentives Referenced in the
		 	Definition of Net Sales
		
	 Appendix 1
	 	IL-21 Related Patents, Cell Line Patents and Construction Strain Patents
	 Appendix 2
	 	[*] Agreement
	 Appendix 3
	 	Principal Terms of USA Co-Promotion Agreement
	 Appendix 4
	 	Novo Nordisk Invoice Instructions
	 Appendix 5
	 	List of Countries Pursuant to Section 9.1
	 Appendix 6
	 	[*]

  

 -iv- 
 * Confidential Treatment Requested. 

 THIRD RESTATED LICENSE AGREEMENT 
 FOR IL-21 EMBODIMENTS 
 This Third Restated License Agreement for IL-21 Embodiments (as defined herein) (“Agreement”) is entered into as of December 3, 2009 (“Effective Date”)
by and between ZymoGenetics, Inc., a Washington corporation (“ZGEN”), and Novo Nordisk A/S, a Danish corporation (“NN”). 
 RECITALS 
 A. ZGEN and NN were parties to an Option and License Agreement,
effective as of November 10, 2000 (as amended, the “Option Agreement”). 
 B. Pursuant to the
Option Agreement, NN exercised its option to receive an exclusive license to various embodiments of IL-21 and ZGEN and NN entered into a License Agreement for IL-21, effective as of August 21, 2001 (the “Original License
Agreement”), that covered a territory comprising all the countries of the world other than USA, Canada and Mexico. 
 C. ZGEN and NN entered into a Restated License Agreement for IL-21, effective as of January 1, 2003 (the “Restated License Agreement”), that superseded the Original License Agreement and added to the
intellectual property subject to the license. 
 D. ZGEN and NN entered into a Second Restated License Agreement for IL-21,
effective as of January 16, 2009 (the “Second Restated License Agreement”), that superseded the Restated License Agreement and removed certain embodiments of IL-21 from the license. 
 E. ZGEN and NN desire to supersede the Second Restated License Agreement with this Agreement, which further adds to the intellectual
property subject to the license and expands the territory to include all the countries of the world. 
 AGREEMENT

 NOW, THEREFORE, the parties, intending to be legally bound, agree as follows: 
 ARTICLE ONE 
 Definitions and Terminology 
  

	1.1	Definitions 

 In addition
to other terms defined elsewhere in this Agreement, words and phrases with initial capitals shall have the meanings stated in this Section 1.1.  
 1.1.1 “Ab Embodiment of IL-21 Product” means: a Product based on an Ab Embodiment of IL-21. 
  

 -1- 

 1.1.2 “Affiliate” means: with respect to a party, any other
business entity which directly or indirectly controls, is controlled by or is under common control with the party. The direct or indirect ownership of at least fifty percent (50%) or, if smaller, the maximum allowed by applicable law, of the
voting securities of a business entity or of an interest in the assets, profits or earnings of a business entity shall be deemed to constitute control of the business entity. For the avoidance of doubt, ZGEN and NN are not (as of the Effective Date)
Affiliates of each other. Notwithstanding the above, the Novo Nordisk Foundation, Novo A/S and Novozymes A/S shall not be considered Affiliates of NN; provided that any transfers of Product by NN to any of such entities shall be at an arm’s
length price. 
 1.1.3 “Agency” means: the FDA, the EMEA or foreign equivalent of either.

 1.1.4 “Annual Plan” is defined in Section 6.2. 
 1.1.5 “Antisense Embodiment of IL-21 Product” means: a Product based on an Antisense Embodiment of IL-21.

 1.1.6 “Applicable Phase IIIB Costs” means: costs incurred by NN or for its account (including
costs incurred outside of the USA and the European Union) that are attributable to trials conducted to support the registration of a Product in the USA and/or European Union that are required by an Agency for the granting of the Regulatory Approval.
This includes trials or long-term extensions of Phase III trials conducted in order to [*] in the [*] at the [*] The post-approval commitments (if any) [*] 
 1.1.7 “Bankruptcy Code” is defined in Section 10.4.  
 1.1.8 “BLA” means: a Biologics License Application, New Drug Application or an application for any other approval from the FDA required to market a Product in the USA or a
non-USA equivalent of any of the foregoing filed with an Agency. 
 1.1.9 “Business Day” means:
any day other than a Saturday, Sunday or other day on which commercial banks in Seattle, Washington or Copenhagen, Denmark are authorized or required by applicable law to close. 
 1.1.10 “Candidate Antibody” means: the Ab Embodiment of IL-21 that constitutes ZGEN’s current
development candidate. 
 1.1.11 “Cell Line Patents” means: the patents and patent applications
set forth in Part B of Appendix 1.  
 1.1.12 “Commercialization Rights” means,
subject to the terms and conditions of this Agreement, including ZGEN’s right to make an Election to Co-Fund: (a) the right to conduct research, use, sample, develop (including clinical development), manufacture, promote, market, offer to
sell, import, export, distribute, sell, and have sold Products, including the use of , contract research organizations; and (b) the right to conduct research, use, sample, develop (including clinical development), manufacture, promote, market,
offer to sell, import, export,

  

 -2- 
 * Confidential Treatment Requested. 

 
distribute, sell and have sold Products together with one or more third parties as part of a co-marketing agreement, strategic partnership, joint venture relationship or the like in which NN or
its Affiliate continues work on research and development of Products; and (c) the right to sublicense one or more third parties to manufacture, promote, market, offer to sell, import, export, distribute, sell or have sold Products. 

1.1.13 “Commercialization Partner” means: a third party to whom NN has extended rights consistent with
Section 1.1.12(b). 
 1.1.14 “Construction Strain Patents” means: the patents
and patent applications set forth in Part C of Appendix 1.  
 1.1.15 “Control” or
“Controlled” means: with respect to a particular item of information or any intellectual property right or other tangible or intangible property, the entity referenced has the ability to exploit and to license or sublicense
the right to exploit the referenced technology or rights, without violating the terms of any agreement or any other arrangement between the entity referenced and a third party. 
 1.1.16 “[*]” is defined in Section 2.8(c). 
 1.1.17 “Election to Co-Fund” is defined in Section 5.1.  
 1.1.18 “EMEA” means: the European Medicines Evaluation Agency or any successor agency thereto. 
 1.1.19 “FDA” means: the United States Food and Drug Administration or any successor agency thereto.

 1.1.20 “First Indication” means: the first disease that a Product is intended to treat.

 1.1.21 “FTE” means a total of [*] weeks or [*] hours per year of work on the development or
commercialization of Products carried out by employees of a party having the appropriate relevant expertise to conduct such activities. 
 1.1.22 “FTE Rate” for both parties until December 31, 2009 will be [*] dollars. Thereafter, the FTE Rate will be adjusted annually by a percentage equal to the amount,
if any, by which the Consumer Price Index for All Urban Consumers, United States City Average, All Items, Not Seasonally Adjusted (Base Period 1982-84 = 100) as published by the United States Department of Labor, Bureau of Labor Statistics
immediately prior to the time of an adjustment differs from such Consumer Price Index as published immediately prior to January 1, 2009. Adjustments shall take place annually on January 1 of each year thereafter. If such Consumer Price
Index is discontinued, unavailable or otherwise substantially revised, a comparable index shall be used. 
 1.1.23
“Generic Product” means: any product marketed by a third party that is not an Affiliate, Commercialization Partner or Sublicensee, that (i) contains the same active pharmaceutical ingredient as the Patent Product
marketed by NN or its Affiliates,

  

 -3- 
 * Confidential Treatment Requested. 

 
Commercialization Partners or Sublicensees and (ii) does not significantly differ from such Patent Product in formulation, quality or effectiveness. For the avoidance of doubt, where the
active pharmaceutical ingredient contained in the Patent Product is an Ab Embodiment of IL-21 or an IL-21 Antagonist Protein, then a Generic Product shall be considered to have the “same active pharmaceutical ingredient as the Patent
Product” when the active pharmaceutical ingredient in the Generic Product has the same sequence as the Ab Embodiment of IL-21 or the IL-21 Antagonist Protein contained in the Patent Product. 
 1.1.24 “GT Embodiment of IL-21 Product” means: a Product based on a GT Embodiment of IL-21. 
 1.1.25 “IL-21 Antagonist Protein” means: a protein, and all species, fragments and modifications of such
polypeptide sequence, encoded by an IL-21 Gene that (i) act solely as an antagonist protein on the IL-21 receptor (i.e., such protein binds the receptor but does not elicit receptor signaling), and (ii) competitively inhibits the binding
of IL-21 Protein on the IL-21 receptor. 
 1.1.26 “IL-21 Antagonist Protein Product” means: a
Product based on an IL-21 Antagonist Protein. 
 1.1.27 “IL-21 Embodiment” means: one or more of
the following: 
 (a) an IL-21 Gene; 
 (b) “GT Embodiments of IL-21”, which are further defined as gene therapy vectors or constructs capable of expressing the IL-21 Protein in vivo; 
 (c) “Ab Embodiments of IL-21”, which are further defined as a polypeptide (including a monoclonal antibody or fusion
protein) or any fragment or derivative thereof that binds to IL-21 Protein; 
 (d) “Antisense Embodiments of
IL-21”, which are further defined as natural or modified polynucleotides, such as triple helix variants or alternative chemistries, that interfere with expression of the IL-21 Protein; or 
 (e) an IL-21 Antagonist Protein. 
 1.1.28 “IL-21 Gene” means: the polynucleotide sequence identified in SEQ ID No. [*] in International application number [*], published as [*], and all species, fragments and
modifications of such polynucleotide sequence that are disclosed in such application or any patents or patent applications included in Appendix 1.  
 1.1.29 “IL-21 Gene Product” means: a Product based on an IL-21 Gene. 
 1.1.30 “IL-21 Protein” means: the protein identified in SEQ ID No. [*] in International application number [*], published as [*] and any protein encoded by an IL-21 Gene,
and all species, fragments and modifications of such polypeptide sequence that are disclosed in such

  

 -4- 
 * Confidential Treatment Requested. 

 
application or any patents or patent applications included in Appendix 1. Notwithstanding the above, any IL-21 Antagonist Protein shall be expressly excluded from the definition of
IL-21 Protein. 
 1.1.31 “IL-21 Related Know-How” means: all inventions, discoveries, know-how,
methodologies, technology, tangible materials (including nucleic acids, peptides, vectors, proteins, and the like) that: 
 (a)
are Controlled by ZGEN as of the Effective Date and either (i) pertain to at least one IL-21 Embodiment or (ii) are otherwise necessary for NN to make, have made, use, sell, offer to sell and import Products in the Territory; and

 (b) are Controlled by ZGEN during the term of this Agreement and both (i) pertain to at least one IL-21 Embodiment and
(ii) are necessary for NN to make, have made, use, sell, offer to sell and import Products in the Territory. 
 For the
avoidance of doubt, IL-21 Related Know-How shall not include: (A) know-how which at the time of disclosure is in the public domain; (B) know-how which, prior to the disclosure from ZGEN to NN (whether before or after the Effective Date),
was in NN’s possession; and (C) know-how developed independently by NN without any use of any confidential ZGEN know-how or confidential ZGEN patent rights whatsoever. 
 1.1.32 “IL-21 Related Patents” means: 
 (a) the patents and patent applications set forth in Part A of Appendix 1; 
 (b) any patents and patent applications that claim (i) an IL-21 Embodiment; (ii) a process, formulation and/or mixture comprising
an IL-21 Embodiment; (iii) a method of making or manufacturing an IL-21 Embodiment; or (iv) a method of using an IL-21 Embodiment and are Controlled by ZGEN during the term of this Agreement and that are necessary for NN to make, have
made, use, sell, offer to sell and import Products in the Territory; 
 (c) all divisional or continuation (in whole or in part)
applications of the applications described in subsection (a) or (b); 
 (d) all patents issuing
from the applications described in subsections (a), (b) and (c); and 
 (e) all
extensions, supplemental protection certificates (including any form of patent term extensions), reissues, reexaminations, substitutions or renewals of the patents described in subsection (d). 
 [*] 
 1.1.33
“IND” means: an Investigational New Drug application, or its foreign equivalent. 
 1.1.34
“JEC” is defined in Section 6.1.1.  
  

 -5- 
 * Confidential Treatment Requested. 

 1.1.35 “Know-How Product” means: a product in final dosage
form that contains an IL-21 Embodiment and is not a Patent Product but that was developed through use of any IL-21 Related Patent, Cell Line Patent, Construction Strain Patent or IL-21 Related Know-How, or which otherwise incorporates or embodies
IL-21 Related Know-How. 
 1.1.36 “Letter Agreement” is defined in Appendix 2. 

 1.1.37 “License Dispute” is defined in Section 4.4.1(b). 
 1.1.38 “Long-Range Plan” is defined in Section 6.2. 
 1.1.39 “[*] Agreement” is defined in Appendix 2. 
 1.1.40 “[*] Commercial License” is defined in Section 2.8(b)(i). 
 1.1.41 “Milestone Events” is defined in Section 3.2(a). 
 1.1.42 “Milestone Fee” is defined in Section 3.2(a). 
 1.1.43 “Net Sales” means: the gross amount invoiced by NN, its Affiliates, Commercialization Partners and
Sublicensees from sales or other dispositions of Products to any independent third party (i.e., non-Affiliate), less the following with respect to the invoiced Product: 
 (a) any credits and allowances on account of retroactive price adjustments or on account of rejection, recall or return of Products previously invoiced; 
 (b) any price reductions, chargebacks and volume rebates and discounts, including cash discounts, as well as administrative, management and
other fees, commissions, reimbursements and similar payments to wholesalers and other third party distributors, government authorities, benefit management organizations, health insurance carriers, hospitals, group purchasing organizations and other
institutions such as [*] as further described on Schedule 3; 
 (c) any sales, excise, turnover, value added, or
similar taxes and any duties and other governmental charges imposed upon the sale of Product(s) that are included in the invoice; 
 (d) the [*] of [*] used for [*], comprising the total of (i) the [*] if such [*] is [*] from [*] or (ii) the [*] of such [*] if such [*] are [*] by NN or its Affiliates. Such [*] shall not include conventional [*]. 
 In the event that the Product is sold as part of a Combination Product (as defined herein) the Net Sales of the Product, for the purposes of
determining royalty payments, shall be determined by multiplying the Net Sales of the Combination Product by the fraction, A/(A + B) where A is the average net sale price of the Product when sold separately in finished form and B is the average net
sale price of the Other Active Agents (as defined herein) sold separately in finished form. In the event that the average sale price of the Product or Other Active Agents

  

 -6- 
 * Confidential Treatment Requested. 

 
cannot be determined, Net Sales of the Product, for the purposes of determining royalty payments, shall be determined by multiplying the Net Sales of the Combination Product by the fraction
C/(C+D), where C is the average per unit inventory cost of the Product and D is the average per unit inventory cost of the Other Active Agents. Inventory costs shall be determined in accordance with NN’s regular accounting methods. 

The fractions set forth in the preceding two paragraphs, as applicable, for a Combination Product shall be calculated once each calendar
year, for a country, and shall be used during all applicable royalty reporting periods for the entire calendar year. When determining the average sale price or inventory cost of a Product or Other Active Agents, data for the preceding calendar year
shall be used for calculating the applicable fraction; provided, however, that with respect to the first year of Net Sales of a Combination Product for a country when there have not been prior separate sales of the corresponding Product, a
reasonable estimate of the applicable fraction shall be used, and an adjustment made after the end of the year for the actual fraction calculated for the year. As used above, the term “Combination Product” means any
pharmaceutical product which comprises (i) a Product and (ii) other pharmaceutically active compounds which are not moieties that are the subject of third-party patents described in Section 4.4 (“Other Active
Agents”). 
 Notwithstanding the foregoing, the Net Sales of a Product in a country shall never be reduced below
fifty percent (50%) of the gross amount invoiced for the Combination Product. 
 Any Product sold or otherwise disposed of
in other than an arm’s-length transaction or for other property (e.g., barter) shall be deemed invoiced at its fair market value in the country of sale or disposition. 
 1.1.44 “Non-Receiving Party” is defined in Section 4.8. 
 1.1.45 “NN Development Technology” means all of the following Controlled by NN or its Affiliates: 

(a) any inventions, discoveries, know-how, methods, processes, data, information, technology, research tools, reagents, compositions,
formulas, biologic and other materials (including nucleic acids, peptides, vectors, proteins, antibodies, assays and the like) relating to Products that: 
 (i) are invented, discovered, developed or otherwise generated by or on behalf of NN or its Affiliates, Commercialization Partners or Sublicensees pursuant to its activities under this Agreement or a
Prior Agreement; or 
 (ii) were actually used by or on behalf of NN or its Affiliates, Commercialization
Partners or Sublicensees in the performance of its activities under this Agreement or a Prior Agreement; and 
  

 -7- 

 (b) all patent applications and patent, trademarks, trade secrets and other
intellectual property rights anywhere in the world covering any of the technology described in Section 1.1.45(a) or otherwise related to the Product. 
 1.1.46 “NN Patent” is defined in Section 9.2. 
 1.1.47 “Original License Effective Date” means: August 21, 2001. 
 1.1.48 “Patent Attorney” is defined in Section 4.4.1(b). 
 1.1.49 “Patent Product” means: a product in final dosage form that contains an IL-21 Embodiment, the making, using, importation, exportation, offer for sale, or sale of
which would infringe, in the absence of the license granted under this Agreement, any unexpired Valid Claim of an IL-21 Related Patent. 
 1.1.50 “Phase I Clinical Trial” means: a human clinical trial intended to obtain initial data regarding the safety of a Product. 
 1.1.51 “Phase IIa Clinical Trial” means: a clinical trial of a Product that utilizes the pharmacokinetic and
pharmacodynamic information obtained from one (1) or more previously conducted Phase I Clinical Trial(s) and/or other Phase IIa Clinical Trial(s) in order to confirm the optimal manner of use of such Product (dose and dose regimens) and to
better determine safety and efficacy. 
 1.1.52 “Phase IIb Clinical Trial” means: a clinical
trial of a Product on sufficient numbers of patients that is designed to provide a determination of safety and efficacy of such Product in the target patient population over a range of doses and/or dose regimens. A successful Phase IIb Clinical
Trial should support moving to Phase III Clinical Trial(s). 
 1.1.53 “Phase IIb Data Package”
means: the following information to be presented by NN to ZGEN in order for ZGEN to determine whether it wants to make an Election to Co-Fund: 
 (a) a report summarizing all material data relating to the Product including: 
 (i) preclinical data and plans; 
 (ii) clinical data and
plans; 
 (iii) manufacturing data and plans; 
 (iv) intellectual property status; and 
 (v) marketing data and commercialization plans; 
 (b) access to all source data for the above; 
 (c) access to all regulatory correspondence related to or material to the Product; and 
  

 -8- 

 (d) any other information NN knows is material to ZGEN’s decision whether it wants to
make an Election to Co-Fund. 
 1.1.54 “Phase III Clinical Trial” means: a clinical trial to
demonstrate efficacy and safety following the approval by NN senior management, in accordance with the policies and procedures as set forth in NN’s Health Care Project Manual. The initiation of a clinical trial that has been prospectively
designed to demonstrate in a patient group (of sufficient size) statistically whether the Product is safe and effective for use in a particular indication, in a manner intended as part of a clinical Phase III program to be sufficient to obtain
Regulatory Approval to market such Product, shall be deemed to be approval by NN senior management. 
 1.1.55
“Phase III Clinical Development” means: with respect to a Product, those activities, including Phase III Clinical Trials (which for purposes of this definition shall include Phase IIIb clinical trials generating
additional safety documentation) and supporting manufacturing and regulatory activities, that are necessary to obtain the Regulatory Approval of such Product in the USA or European Union. Phase III Clinical Development shall not include
(a) Phase IV Clinical Trials or post-approval clinical studies regulated as a condition of Regulatory Approval in the USA or European Union or (b) commercial scale up and process development, including process transfer and validation and
assay transfer and validation conducted solely for commercialization of the Product and not for Regulatory Approval of the Product. 
 1.1.56 “Phase III Costs” means: the costs incurred by NN or for its account during the term of this Agreement in accordance with an Annual Plan (as defined herein) that are specifically identifiable or
allocable to the Phase III Clinical Development of a Product and that are directed to achieving Regulatory Approval of such Product in the USA and European Union (including costs incurred outside of the USA and the European Union). The Phase III
Costs shall include (a) amounts that NN pays to third parties involved in the Phase III Clinical Development of a Product (excluding any royalties, which are addressed in Section 4.4), (b) all internal costs calculated
at the FTE Rate incurred by NN in connection with the Phase III Clinical Development of such Product and (c) Applicable Phase IIIB Costs. 
 1.1.57 “Phase III Stop/Go Decision” means: the decision on termination or continuation of the development of a Product into Phase III Clinical Trials (i.e., the [*]). The
Phase III Stop/Go Decision provides [*] of all available [*] along with [*] is also included in the [*]. A report encompassing [*] supporting the [*] is also prepared for approval. 
 1.1.58 “Phase IV Clinical Trials” means: a product support clinical trial of a Product commenced after
receipt of Regulatory Approval in the country where such trial is conducted. A Phase IV Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, investigator-sponsored clinical trials and trials required by an
Agency for safety or other reasons that otherwise fit the foregoing definition. 
 1.1.59
“Product” means: either a Know-How Product or a Patent Product. 
  

 -9- 
 * Confidential Treatment Requested. 

 1.1.60 “Prior Agreements” means: the Option Agreement,
Original License Agreement, Restated License Agreement, Second Restated License Agreement and the Confidentiality Agreement, dated January 15, 2008. 
 1.1.61 “Reasonable Commercial Efforts” means: the exertion on a substantially continuous basis of efforts as would normally be devoted to the applicable task by a motivated
commercial party with similar resources to those of the applicable party taking into account, without limitation, consideration of the [*], its [*], the [*], [*] factors, and other [*] factors. Notwithstanding the foregoing, to the extent that the
performance of a party’s responsibilities hereunder is adversely affected by the other party’s failure to perform its responsibilities hereunder, such party will not be deemed to have failed to use its Reasonable Commercial Efforts in
performing such responsibilities. 
 1.1.62 “Receiving Party” is defined in
Section 4.8.  
 1.1.63 “Regulatory Approval” means: the authorization by an
appropriate Agency to market and sell a Product in a jurisdiction. 
 1.1.64 “[*]” is defined in
Section 12.14.  
 1.1.65 “Safety Reasons” is defined in
Section 10.3.  
 1.1.66 “Second Indication” means: the second disease that a
Product is intended to treat. 
 1.1.67 “Sublicensee” means: a third party to whom NN has
extended a sublicense consistent with Section 1.1.12(c). 
 1.1.68 “Submission
Milestone” means: the submission of the BLA to the FDA. The Submission Milestone is passed when the file has been delivered to, and accepted by, the FDA. The Submission Milestone ensures that all documentation determined by NN to be
sufficient to satisfy the applicable requirements for Regulatory Approval is completed and collected and that the BLA is received by the FDA. 
 1.1.69 “Territory” means: all the countries of the world. 
 1.1.70 “Third Indication” means: the third disease that a Product is intended to treat. 
 1.1.71 “Valid Claim” means: (a) a claim of a pending IL-21 Related Patent that has been pending for less than [*] years from the filing date of the earliest filed patent application anywhere in the world
from which such pending IL-21 Related Patent claims priority and has not been cancelled, withdrawn or abandoned or (b) an unexpired, granted IL-21 Related Patent that has not: (i) been disclaimed, withdrawn, canceled, or abandoned; or
(ii) been finally rejected or held invalid by a decision of a patent-granting authority beyond right of review or appeal; or (iii) been held invalid or unenforceable in an unappealable decision of a court or competent body having
jurisdiction (including a decision which was appealable, but which was not timely appealed). For the avoidance of doubt, if a claim of a patent application within the IL-21 Related

  

 -10- 
 * Confidential Treatment Requested. 

 
Patents that issues or grants after [*] years from the filing date of the earliest filed patent application anywhere in the world from which such pending IL-21 Related Patent claims priority,
such claim from such issued or granted IL-21 Related Patent shall be considered a valid claim in accordance with clause (b) above. 
  

	1.2	Terminology 

 Where words
and phrases are used in this Agreement in the singular, such usage is intended to include the plural forms where appropriate to the context, and vice versa. The words “including,” “includes” and
“such as” are used in a non-limiting sense and have the same meaning as “including without limitation” and “including, but not limited to.” “Herein”
means anywhere in this Agreement. “Hereunder” and “hereto” mean under or pursuant to any provision of this Agreement. References to Articles, Sections, Schedules and Appendices are to Articles,
Sections, Schedules and Appendices of this Agreement unless otherwise specified. All Schedules and Appendices annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Any
capitalized terms used in any Schedule or Appendix but not otherwise defined therein, shall have the meaning as defined in this Agreement. 
 ARTICLE TWO 
 License 
  

	2.1	License Grant 

 Subject to
the terms and conditions of this Agreement (including Section 2.4), ZGEN hereby grants to NN the exclusive (even as to ZGEN) right in the Territory to practice all Commercialization Rights under the IL-21 Related Patents and IL-21
Related Know-How for all Products. Subject to Section 2.2, NN shall not use the IL-21 Related Patents or IL-21 Related Know-How for any other purpose. 
  

	2.2	Nonexclusive License Grant – IL-21 Protein 

 Subject to the terms and conditions of this Agreement, ZGEN further grants to NN the nonexclusive right to make and use worldwide the IL-21 Protein [*] only as required to develop (including to clinically
develop), produce, and commercialize Products. 
  

	2.3	Sublicensing by NN 

 (a)
NN may sublicense its rights granted pursuant to Section 2.1 without ZGEN’s written approval; provided that such sublicense is granted in accordance with the provisions of this Section 2.3. NN may
sublicense its rights granted pursuant to Section 2.2 only upon ZGEN’s prior written approval, such approval not to be unreasonably withheld. Each sublicense shall be in writing, shall be subject to and consistent with the
terms of this Agreement, and shall contain provisions substantially identical to Sections 2.6(b), 2.7(b) and 4.7, Articles Seven through Eight, and Sections 10.6, 10.7, 10.9, 12.3
and 12.4. Upon execution of each sublicense NN shall promptly provide ZGEN with a copy of each such sublicense (together with an English-language translation where necessary) and of each amendment and notice of termination of each
sublicense. 
  

 -11- 
 * Confidential Treatment Requested. 

 (b) Each sublicense shall be terminable upon termination of this Agreement upon ZGEN’s
written request, and NN shall include a statement to that effect in each sublicense. Notwithstanding the above, ZGEN will consider in good faith maintaining such sublicense upon termination of this Agreement with a sublicensee who is in full
compliance with the terms of the applicable sublicense agreement. 
  

	2.4	ZGEN Reservation of Rights 

 ZGEN reserves for itself, its Affiliates, commercialization partners and licensees, the nonexclusive right to make and use in the Territory the IL-21 Embodiments as required for the development (including clinical development), production,
and commercialization of products based on the IL-21 Protein. 
  

	2.5	Transition Plan 

 Within
ninety (90) days of the Effective Date, the parties shall agree on a plan (the “Transition Plan”) pursuant to which ZGEN shall: (i) fully disclose to NN the IL-21 Related Patents and IL-21 Related Know-How to the
extent not previously disclosed and (ii) transfer to NN the manufacturing processes relating to the Candidate Antibody as promptly as practicable, including the items set forth in Schedule 1 attached hereto. NN will reimburse ZGEN
for its actual costs incurred in accordance with the Transition Plan or otherwise approved in writing by NN. Such costs shall include all internal costs calculated at the FTE Rate incurred by ZGEN in connection with the Transition Plan and all
amounts that ZGEN pays to third parties to the extent approved in advance by NN, such approval not to be unreasonably withheld. The parties anticipate that the activities to be covered by the Transition Plan will be substantively complete within six
(6) months after the Effective Date. 
  

	2.6	Development 

 (a) Subject
to the terms and conditions of this Agreement, including Section 2.6(b), NN shall have sole control and decision-making authority over the development of Products; provided that NN’s decisions are reflected in the Long-Range
Plan or Annual Plan. 
 (b) NN shall use its Reasonable Commercial Efforts to develop, manufacture and obtain Regulatory
Approval for one or more Products, as soon as reasonably practicable, in one or more indications from Agencies in (i) the USA, (ii) Great Britain, (iii) Germany, (iv) France, (v) Italy, (vi) Spain, (vii) Japan and
(viii) each of Brazil, Russia, India and China; provided that, in the case of any of the four countries listed in this subsection (viii), NN considers, following consultation with ZGEN, including at the JEC (as defined herein),
that it represents a reasonable commercial opportunity to NN. 
  

 -12- 

 (c) Except as expressly set forth elsewhere in this Agreement, NN shall fund and shall bear
one hundred percent (100%) of the costs of the development of Products hereunder in the Territory, including the costs of activities performed by ZGEN pursuant to this Agreement. 
  

	2.7	Commercialization 

 (a)
Subject to the terms and conditions of this Agreement, including Section 2.7(b), NN shall have sole control and decision-making authority over the commercialization of Products; provided that NN’s decisions are reflected in
the Long-Range Plan or Annual Plan. 
 (b) NN shall use its Reasonable Commercial Efforts to commercialize one or more Products,
as soon as reasonably practicable, in one or more indications in (i) the USA, (ii) Great Britain, (iii) Germany, (iv) France, (v) Italy, (vi) Spain, (vii) Japan and (viii) each of Brazil, Russia, India and China
provided that, in the case of any of the four countries listed in this subsection (viii), NN considers, following consultation with ZGEN, including at the JEC (as defined herein), that it represents a reasonable commercial opportunity
to NN. 
 (c) Except as expressly set forth elsewhere in this Agreement, NN shall fund and shall bear one hundred percent
(100%) of the costs of commercializing Products hereunder in the Territory, including amounts payable to ZGEN under the USA Co-Promotion Agreement. 
  

	2.8	[*] Technology 

 (a) Under
the [*] Agreement ZGEN may, and ZGEN hereby does, grant NN an exclusive sublicense under the [*] Technology (as defined in the [*] Agreement) to develop, make, have made, import, have imported, use, offer for sale, sell and have sold the Products.
NN acknowledges that it has been given access to a copy of the [*] Agreement, and agrees that its sublicense to the [*] Technology is subordinate thereto. 
 (b) ZGEN agrees that during the term of this Agreement it shall: 
 (i) not terminate the commercial license of [*] under the [*] Agreement that relates to the Candidate Antibody (the “[*] Commercial License”) or the Letter Agreement as it relates to the [*] Commercial License
without the prior written consent of NN; 
 (ii) not, without the prior written consent of NN, amend, modify,
waive compliance with or assign, or agree to any amendment, modification, waiver of compliance with or any assignment of any rights or obligations under the [*] Commercial License or the Letter Agreement as it relates to the [*] Commercial License,
including rights and obligations relating to royalties, fees, milestone achievements and payments therefor, diligent efforts, reports, regulatory filings, research, patent filings, maintenance and enforcement and confidentiality, insofar as any such
amendment, modification, waiver of compliance with or assignment or agreement to do any of the foregoing could reasonably be expected to affect any of NN’s rights and obligations hereunder; 
  

 -13- 
 * Confidential Treatment Requested. 

 (iii) at all times comply with all provisions of the [*] Commercial License
and the Letter Agreement as it relates to the [*] Commercial License and fulfill all of its obligations thereunder, other than those which NN has agreed to fulfill directly hereunder. 
 (c) In order to [*], NN will be required to [*]. As a condition precedent to the effectiveness of this Agreement, the parties, together with
[*] shall have [*] in the form attached hereto as Appendix 6.  
 ARTICLE THREE 
 Upfront and Milestone Fees 
  

	3.1	Execution Fee 

 In partial
consideration for ZGEN’s entering into this Agreement and making the license grants hereunder, NN shall pay to ZGEN an execution fee of Twenty Four Million Dollars ($24,000,000), which amount shall be non-creditable and non-refundable, and
shall be paid within ten (10) Business Days after the Effective Date. 
  

	3.2	Milestone Fees 

 (a)
Within ten (10) Business Days after achievement by NN or its Affiliate, Commercialization Partner or Sublicensee of each milestone event stated below (the “Milestone Events”), NN shall pay ZGEN the corresponding
milestone fee (the “Milestone Fees”). 
  

										
	 Milestone Event
	  	 Milestone Fee
for
 First
Indication ($)
	 	 	 Milestone Fee
for
 Second
Indication ($)
	 	 	 Milestone Fee
 for
 Third
Indication ($)
	 
	 Filing of IND with an Agency
	  	1,500,000	  	 	—  	  	 	—  	  
	 Initiation (i.e., first patient or healthy volunteer, first dose) of the first Phase I Clinical Trial
	  	8,500,000	  	 	[	*] 	 	[	*] 
	 [*]
	  	[	*] 	 	[	*] 	 	[	*] 
	 [*]
	  	[	*] 	 	[	*] 	 	[	*] 
	 [*]
	  	[	*] 	 	[	*] 	 	[	*] 
	 [*]
	  	[	*] 	 	[	*] 	 	[	*] 
	 [*]
	  	[	*] 	 	[	*] 	 	[	*] 
	 [*]
	  	[	*] 	 	[	*] 	 	[	*] 
	 [*]
	  	[	*] 	 	[	*] 	 	[	*] 
	 Total
	  	[	*] 	 	[	*] 	 	[	*] 

 (b) All
Milestone Fees hereunder shall be payable only for the first IL-21 Gene Product, GT Embodiment of IL-21 Product, Ab Embodiment of IL-21 Product, Antisense Embodiment of IL-21 Product and/or IL-21 Antagonist Protein Product, as the case may be, that
achieves the relevant Milestone Event for the relevant indication. For the avoidance of doubt, if

  

 -14- 
 * Confidential Treatment Requested. 

 
multiple IL-21 Gene Products, GT Embodiment of IL-21 Products, Ab Embodiment of IL-21 Products, Antisense Embodiment of IL-21 Products and/or IL-21 Antagonist Protein Products, as the case may
be, proceed through development, NN shall pay Milestone Fees only for the first such IL-21 Gene Product, GT Embodiment of IL-21 Product, Ab Embodiment of IL-21 Product, Antisense Embodiment for IL-21 Product and/or IL-21 Antagonist Protein Product
to pass each Milestone Event; provided that if an IL-21 Gene Product, GT Embodiment of IL-21 Product, Ab Embodiment of IL-21 Product, Antisense Embodiment for IL-21 Product and/or IL-21 Antagonist Protein Product, as the case may be, achieves one or
more Milestone Events but is not developed further the remaining Milestones Fees will be payable if a second IL-21 Gene Product, GT Embodiment of IL-21 Product, Ab Embodiment of IL-21 Product, Antisense Embodiment for IL-21 Product and/or IL-21
Antagonist Protein Product, as the case may be, achieves the remaining Milestone Events. Each Milestone Fee shall be non-refundable and non-creditable against any other amount payable by NN under this Agreement. 
  

	3.3	Milestone Fees under [*] Agreement 

 NN shall pay to ZGEN (or, at ZGEN’s request, directly to [*]) [*] percent ([*]%) of the milestone fees paid or payable in accordance with the [*] Agreement upon the achievement of the [*] milestone
events set forth in the [*] Agreement. For clarity, ZGEN shall pay [*] percent ([*]%) of the milestone fee payable under the [*] Agreement upon the achievement of the [*] milestone event set forth in the [*] Agreement, and NN shall not be required
to reimburse ZGEN for such payment. 
 ARTICLE FOUR 
 Royalties 
  

	4.1	Patent Products 

 NN shall
pay a royalty to ZGEN on a country by country basis for each Patent Product made, used, imported, offered for sale or sold by NN, its Affiliates, Commercialization Partners or Sublicensees. NN’s obligation to pay royalties for a Patent Product
in a country shall expire on the expiration date of the last-to-expire IL-21 Related Patent with a Valid Claim which would be infringed, in the absence of the license granted under this Agreement, by the making, using, importation, exportation,
offer for sale, or sale of the Patent Product in such country (i.e., when the Patent Product ceases being a “Patent Product” as defined and thereafter may become a “Know-How Product”). The royalties shall be calculated by
multiplying the applicable royalty rate by the Net Sales of such Patent Product in such country. Unless ZGEN makes an Election to Co-Fund and has not revoked such election pursuant to Section 5.6, the applicable royalty rate shall
be as set forth below. 
  

				
	 Aggregate Net Sales in Territory
 in a calendar year
	  	 Royalty Rate for
Such Net Sales in Territory

	 
	 Up to and including $[*]
	  	[	*] 
	 Greater than $[*] and up to and including $[*]
	  	[	*] 
	 Greater than $[*]
	  	[	*] 

  

 -15- 
 * Confidential Treatment Requested. 

	4.2	Know-How Products 

 NN
shall pay a royalty to ZGEN on a country by country basis for each Know-How Product made, used, imported, offered for sale or sold by NN, its Affiliates, Commercialization Partners or Sublicensees. NN’s obligation to pay royalties for each
Know-How Product shall expire in each country on the date [*] years after the first sale of the Product in such country (“Know-How Royalty Period”). The royalties shall be calculated by multiplying the applicable royalty rate
by the Net Sales of such Know-How Product. Unless ZGEN makes an Election to Co-Fund and has not revoked such election pursuant to Section 5.6, the applicable royalty rate shall be (i) [*] percent ([*]%) or (ii) if
(w) NN exercises its [*] pursuant to Section 9.2(c), (x) there is an [*] that [*], (y) ZGEN has not [*], and (z) NN does not [*] [*] percent ([*]%), of the rate determined in accordance with the table set forth
in Section 4.1. If the last-to-expire IL-21 Related Patent expires in a country prior to the end of the Know-How Royalty Period, then NN shall pay to ZGEN Know-How Product royalties in such country for the remainder of the
Know-How Royalty Period. 
  

	4.3	Not Additive; Aggregation 

 (a) The royalties under Sections 4.1 and 4.2 and Sections 5.3.2(a) and (b) are not additive. NN shall pay the highest applicable royalty rate only. 
 (b) All Net Sales in the Territory whether covered by Section 4.1, 4.2 or 5.3.2 shall be aggregated for
purposes of determining which royalty rate set forth in the table in Section 4.1 or 5.3.2(a) is payable. 
  

	4.4	Third Party Agreements 

 4.4.1 General 
 (a) Except for those paid or payable in accordance with the [*] Agreement (as defined herein),
NN shall pay one hundred percent (100%) of all third party royalties necessary in order to commercialize any Products in accordance with this Agreement. NN shall pay to ZGEN the royalties set forth in this Agreement except to the extent that a
third party (that is not an Affiliate, Commercialization Partner or Sublicensee of NN) has an issued patent in a country claiming a composition of matter or a method of use that the parties agree is necessary to commercialize a Product in such
country. In such an event, NN shall be entitled to offset, on a country by country basis, [*] percent ([*]%) of the royalties paid to such third party against royalties due and owing to ZGEN pursuant to Section 4.1, 4.2 or
5.3.2(a) or (b), as applicable, for such Product i.e., whether such Product is a Patent Product or a Know-How Product. 
 (b) If the parties are unable to reach agreement that a license to a patent is necessary (“License Dispute”), then the parties shall select by mutual agreement within fifteen
(15) days a patent attorney from a recognized law firm (the “Patent Attorney”) with suitable expertise in the field of intellectual property in pharmaceuticals to settle such License Dispute. At the time of selection of
the Patent Attorney, the Patent Attorney’s firm shall not be rendering (and during the preceding two-year period shall not have rendered) services to either party. The Patent Attorney

  

 -16- 
 * Confidential Treatment Requested. 

 
shall have agreed to sign a confidentiality agreement undertaking that all documents exchanged by the parties in reference to the License Dispute, including the Patent Attorney’s decision
resolving the License Dispute, shall be maintained in confidence and save as required by applicable law shall not be used for any purpose other than deciding whether a license is necessary. The parties shall seek to obtain a decision on the License
Dispute within sixty (60) days from the date the Patent Attorney is chosen by the parties. The decision of the Patent Attorney as to whether a license is necessary shall be final. 
 (c) Even if the Patent Attorney decides that a license is not necessary, NN may, in its absolute discretion, enter into such a license;
provided NN shall not be entitled to offset any amounts paid or payable under such agreement against the royalties owed to ZGEN under this Agreement. 
 4.4.2 Royalties under [*] Agreement 
 (a) NN shall pay to ZGEN (or, at
ZGEN’s request, directly to [*]) [*] percent ([*]%) of the royalties paid or payable in accordance with the [*] Agreement. 
 (b) To the extent ZGEN’s obligation to pay royalties under the [*] Agreement extends beyond the Know-How Royalty Period in a country, NN shall pay to ZGEN (or, at ZGEN’s request, directly to [*]) [*] percent ([*]%) of the
royalties paid or payable in accordance with the [*] Agreement on sales of Products in such country. 
 (c) There shall be no
offset against the royalties set forth in this Agreement for NN’s payments with respect to the [*] Agreement. 
  

	4.5	Generic Products 

 If, in
any country in the Territory, Generic Products reach a market share equal to or higher than [*] percent ([*]%) of the local market for a Product, then the royalty rate on such Product otherwise applicable shall be reduced with respect to such
country according to the following scale: 
  

			
	 Market Share of the Generic Product
	  	 Percentage of Reduction
of the Royalty Rates
Otherwise
Applicable

	 [*]%
	  	[*]% reduction
	 Greater than [*]%
	  	[*]% reduction
	 Greater than [*]%
	  	[*]% reduction
	 Greater than [*]%
	  	[*]% reduction
	 Greater than [*]%
	  	[*]% reduction

  

	4.6	Additive Offsets; Minimum Royalties 

 The royalty offsets and reductions for Products set forth in Sections 4.4 and 4.5 shall be additive; provided that, the minimum royalty payable by NN to ZGEN (i.e., after
reducing the

  

 -17- 
 * Confidential Treatment Requested. 

 
royalty rate pursuant to Section 4.4.1 and 4.5 and deducting amounts paid by ZGEN to [*], Inc. under Section 4.4.2) shall never be reduced
below [*] of the royalties set forth, in the case of Patent Products, in Sections 4.1 or 5.3.2(a) and, in the case of Know-How Products, Sections 4.2 or 5.3.2(b). 
  

	4.7	Payments and Reports 

 (a) Royalties payable pursuant to this Agreement shall be due quarterly within forty-five (45) days following the end of each calendar quarter for Net Sales in such calendar quarter. All sales in
foreign currencies shall be converted into United States dollars using the rate of exchange quoted by Bank of America and its successor(s) on the last Business Day of the calendar quarter in which the sales were made. Each such payment shall be
accompanied by a statement of Net Sales for the quarter (including number of units), applicable exchange rates and the calculation of royalties payable hereunder by Product and country. All Milestone Fees, royalties and all other amounts which are
overdue under this Agreement will bear interest at the rate of one and one-half percent (1 1/2%) per month from the date due through the date of payment. NN shall keep and shall cause its Affiliates, Commercialization Partners and Sublicensees to keep complete, true and accurate records for
at least five (5) years for the purpose of showing the derivation of all Milestone Fees and royalties payable under this Agreement. ZGEN’s duly accredited representatives, which are reasonably acceptable to NN, shall have the right to
inspect and audit such records at any time during reasonable business hours upon reasonable prior notice to NN or any of its Affiliates, Commercialization Partners or Sublicensees, but such right will not be exercised more often than annually (it
being understood that a single exercise of such right may include a series of related or continuing inspections and audits). 
 (b) Except for the execution fee, Milestone Fees and royalties, all payments made under this Agreement will only be made pursuant to NN’s receipt of an invoice prepared in adherence to the guidelines set forth in Appendix
4. Payments will be made within forty-five (45) days after NN’s receipt of each such invoice. For the avoidance of doubt, all bank fees related to receipt of interbank transfers must be borne by the recipient. 
  

	4.8	Taxation of Payments 

 Each party shall be responsible for and shall bear any taxes levied upon payments received by such party (such party, the “Receiving Party”), and authorizes the other party (the “Non-Receiving
Party”) to withhold such taxes from the payments which are payable to the Receiving Party in accordance with this Agreement if the Non-Receiving is either required to do so under the applicable tax laws or directed to do so by an agency
of the relevant government. Upon the Receiving Party’s written request, the Non-Receiving Party shall, with respect to the laws of Denmark (if NN is the Non-Receiving Party), or the laws of the United States or the State of Washington (if ZGEN
is the Non-Receiving Party) and at no cost to the Receiving Party, support the Receiving Party in its legal efforts to minimize any such withholding taxes, and provide the Receiving Party with information about and necessary for any documentation
needed to reduce withholding to a legal minimum. In addition, if either party anticipates witholding taxes in accordance with this Section 4.8, it will give the other party prior written notice thereof,

  

 -18- 
 * Confidential Treatment Requested. 

 
and the parties will cooperate reasonably to obtain available exemptions or relief from any applicable withholding tax under the provisions of any applicable tax laws or under any other
applicable laws, including double tax treaties. 
  

	4.9	Currency Blockage 

 If the
laws or regulations of another country prevent the conversion of its currency into United States dollars for the payment of royalties, NN will either (a) pay such royalties by depositing the currency of the other country into a bank account
designated by ZGEN in that country or (b) if permitted by law, pay such royalties in the currency of the country in question to ZGEN’s designee in that country. 
 ARTICLE FIVE 
 Co-Funding Phase III Clinical Development and USA
Co-Promotion 
  

	5.1	Election to Co-Fund 

 ZGEN
shall have, subject to this Article Five, the right to elect to co-fund the Phase III Clinical Development of a Product (an “Election to Co-Fund”) and co-fund such costs in which case the royalties payable to
ZGEN with respect to Net Sales of such Product in the USA shall be adjusted as provided in Section 5.3.2 (subject to the provisions of Section 5.3.2(c)) and ZGEN shall have the option to co-promote as described
in Section 5.3.3. 
  

	5.2	Procedure 

 (a) NN shall
provide to ZGEN the Phase IIb Data Package no later than [*] but in any event prior to the date on which the first Product passes the [*]. 
 (b) To exercise its Election to Co-Fund, ZGEN must provide written notice to NN and pay to NN a non-refundable opt-in fee of Ten Million Dollars ($10,000,000) within [*] of receipt of the Phase IIb Data
Package, in accordance with payment instructions that shall be provided by NN to ZGEN prior to the date on which such payment is due. Subject to Section 5.6, any Election to Co-Fund shall be irrevocable. 
  

	5.3	Consequences of Election to Co-Fund 

 Following an Election to Co-Fund: 
 5.3.1 Cost Sharing 
 The parties shall share Phase III Costs as described in Section 5.4.  
 5.3.2 Royalties on Net Sales in the USA 
 (a) Rather than the royalty rates set forth in Section 4.1, the royalty rate applicable to Net Sales of a Patent Product in the USA shall be the rate determined in accordance with the
table set forth below. 
  

 -19- 
 * Confidential Treatment Requested. 

				
	 Aggregate Net Sales in Territory
 in a calendar year
	  	 Royalty Rate for
Such Net Sales in USA
	 
	 Up to and including $[*]
	  	[	*]% 
	 Greater than $[*] and up to and including $[*]
	  	[	*]% 
	 Greater than $[*]
	  	[	*]% 

 (b) Rather
than the royalty rates set forth in Section 4.2, the royalty rate applicable to Net Sales of a Know-How Product in the USA shall be either (i) [*] percent ([*]%) or (ii) if (w) NN exercises its [*] pursuant to
Section 9.2(c), (x) there is an [*] that [*], (y) ZGEN has not [*], and (z) NN does not [*], [*] percent ([*]%), of the rate determined in accordance with the table set forth in Section 5.3.2(a).

 (c) For the avoidance of doubt, the royalty rates set forth in Sections 4.1 and 4.2 shall
continue to apply to Net Sales of Patent Products and Know-How Products outside the USA, and Net Sales shall be aggregated in accordance with Section 4.3(b). 
 5.3.3 ZGEN’s Right to Co-Promote in USA 
 Following an Election to Co-Fund, ZGEN will have the right (but not the obligation) to co-promote the Product to which such Election to Co-Fund relates in the USA as contemplated in
Section 5.5.  
  

	5.4	Phase III Costs 

 5.4.1
Cost Sharing of Phase III Costs 
 All Phase III Costs relating to a Product for which ZGEN made an Election to Co-Fund
incurred after ZGEN’s receipt of the Phase IIB Data Package shall be borne by the parties as set forth in the following table: 
  

				
	 Name
	  	 Percentage of Phase III Costs
	 
	 NN
	  	85	% 
	 ZGEN
	  	15	% 

 5.4.2
Accounting and Reconciliation 
 (a) NN shall submit to ZGEN no later than the twenty fifth
(25th) day of the last month of each calendar quarter
a written estimate of Phase III Costs incurred by it during such calendar quarter. In addition, NN shall report to ZGEN within thirty (30) days after the end of each calendar quarter with regard to the Phase III Costs incurred by it during such
calendar quarter. Such report shall specify in reasonable detail all expenses included in such Phase III Costs during such calendar quarter and, upon ZGEN’s reasonable request, NN shall provide invoices and other supporting documentation.
NN’s report shall include, in addition to the Phase III Costs actually incurred by it during the relevant calendar quarter, a comparison of the amounts budgeted in the applicable Annual Plan for such activities and an explanation of any
significant variances. The parties’ Finance Contacts (as defined herein) shall facilitate the reporting of Phase III Costs hereunder and the resolution of any questions concerning such reports. 
  

 -20- 
 * Confidential Treatment Requested. 

 (b) NN shall record and account for its FTE effort for the Phase III Clinical Development of
a Product to the extent that such FTE efforts are included in Phase III Costs that are, or may in the future be, shared under this Agreement, and shall report such FTE effort to the Finance Contacts on a quarterly basis. Except to the extent
provided herein, NN shall calculate and maintain records of FTE effort incurred by it in the same manner as used for other products it develops. 
 (c) The Phase III Costs shall be accounted for by NN hereunder in accordance with the following cost accounting principles: 
 (i) The parties intend that all costs defined herein are to be: (A) determined consistent with generally accepted
accounting principles and (B) allocated among projects and activities by NN in a good faith attempt to calculate the relative cost of each of such projects and activities in a manner consistent with NN’s customary practices. 
 (ii) The following guidelines shall be used in determining amounts chargeable to Phase III Costs. 
 (A) If a cost is specifically and exclusively incurred for Phase III Clinical Development of a Product solely to support a
Regulatory Approval in a country other than USA or outside the European Union, then none of such cost shall be included in Phase III Costs. 
 (B) If a cost is incurred for Phase III Clinical Development of a Product to support a Regulatory Approval in USA or the European Union, and [*] connection with such Phase III Clinical Development [*],
then the cost shall be [*]; provided that, if in connection with the incurrence of such cost there are [*] with respect to development of a Product in a [*], then such [*] shall be [*] 
 (iii) NN shall track FTEs by functional area and by quarter in a manner consistent with its project cost system or using such
other time tracking system as NN applies with respect to its internal programs. In general, these project cost systems shall report actual time spent on specific projects by an individual, and apply the FTE Rate. The Finance Contacts shall determine
the costs of which individuals or functions will be reimbursed through the application of an FTE Rate, which FTE Rate shall be determined in accordance with the definition thereof. 
 (d) Within forty-five (45) days after the end of each of the first three (3) calendar quarters and, for the last calendar quarter
in a calendar year, within sixty (60) days after the end of such calendar quarter, ZGEN shall make a reconciling payment to NN to achieve the appropriate allocation of Phase III Costs provided for in Section 5.4.1. The
Finance Contacts shall seek to resolve any questions related to such accounting statements within fifteen (15) days following receipt by ZGEN of NN’s report. 
  

 -21- 
 * Confidential Treatment Requested. 

 (e) Any expenses incurred by NN for development activities related to a Product that do not
fall within the definitions of Phase III Costs shall be borne solely by NN. In addition, any expenditure or cost that exceeds the amount set forth in the then applicable Annual Plan by ten percent (10%) or more for a calendar year or any
unbudgeted cost that is incurred by NN shall be borne by NN (in the amount of the excess), with the exception of costs incurred due to safety or regulatory reasons not foreseen at the date of the applicable Annual Plan; provided that NN shall
consult with ZGEN prior to incurring any such costs. 
 (f) NN shall keep detailed records of the Phase III Costs it incurs,
including all supporting documentation for such expenses. NN shall keep such records for at least seven (7) years after the date that such expense was incurred. ZGEN shall have the right at reasonable times and upon reasonable prior notice to
review NN’s records to confirm the accuracy of NN’s costs and reports with respect to Phase III Costs. 
  

	5.5	Co-Promotion in USA 

 5.5.1 USA Co-Promotion Agreement 
 Promptly following an Election to Co-Fund, NN and ZGEN shall negotiate an
agreement for the co-promotion of the Product in the USA (the “USA Co-Promotion Agreement”) that contains provisions consistent with Appendix 3 as well as other terms customary for co-promotion agreements. The
parties intend that no later than [*] following the exercise by ZGEN of its Election to Co-Fund, the final form of the USA Co-Promotion Agreement shall be available for review by ZGEN for the purpose of its determining whether it wishes to
co-promote the Product in the USA. However, if the parties after good faith efforts to reach reasonable terms on the USA Co-Promotion Agreement are unable to reach agreement within the foregoing [*] period, the dispute shall be referred to the chief
executive officers of NN and ZGEN. If the chief executive officers are unable to resolve a dispute within [*] days after the end of the forgoing [*] period, [*]. Notwithstanding the above, upon mutual agreement in writing, the chief executive
officers of NN and ZGEN may extend the period for resolving a dispute beyond [*] days. 
 5.5.2 Right to Co-Promote

 Subject to Section 5.5.1, no later than thirty (30) days after ZGEN receives written notice from
NN that the first Product for which ZGEN made an Election to Co-Fund has passed the [*], ZGEN shall give NN written notice of its decision whether or not to co-promote such Product in the USA (which decision shall apply to all Indications of such
Product). If ZGEN confirms that it desires to co-promote, the parties shall proceed to execute the USA Co-Promotion Agreement that has been negotiated in accordance with Section 5.5.1. If and upon such terms as mutually agreed
upon by the parties following the execution of the USA Co-Promotion Agreement, ZGEN’s co-promotion obligations with respect to the applicable Product may be limited to certain specified indications of such Product. 
  

 -22- 
 * Confidential Treatment Requested. 

	5.6	ZGEN’s Right to Opt Out of Co-Funding 

 (a) ZGEN shall have the right to cease contributing to Phase III Costs for a Product (“Opt Out of Co-Funding”). ZGEN may exercise its right to Opt Out of Co-Funding at any time by
written notice to NN; provided that the effective date of the Opt Out of Co-Funding shall be the last day of the second full calendar quarter following the calendar quarter in which the notice is given. 
 (b) ZGEN’s responsibility for a pro rata share of the Phase III Costs shall end upon the effective date of the Opt Out of Co-Funding;
provided that ZGEN shall continue to be responsible for its pro rata share of such costs incurred during the period prior to the effective date of the Opt Out of Co-Funding in accordance with the applicable Annual Plan in effect on the date the
notice was given. 
 (c) Upon the effective date of the Opt Out of Co-Funding, ZGEN’s right to co-promote Products under
Section 5.5 shall terminate, and the royalty rates set forth in Sections 5.3.2(a) and (b) shall cease to apply to Net Sales of Products in the USA. 
 ARTICLE SIX 
 Relationship Management 

 

	6.1	Joint Executive Committee 

 6.1.1 Formation; Composition; Decisions 
 (a) Following an Election to Co-Fund, the parties’ shall form a
joint executive committee (the “Joint Executive Committee” or “JEC”) to manage their relationship in connection with this Agreement. Each party shall appoint its representatives on the initial JEC in
writing within thirty (30) days following the Election to Co-Fund and shall promptly thereafter notify the other party in writing of such appointment. 
 (b) The JEC shall have up to six (6) members. ZGEN and NN shall each appoint at least two (2) members. Each party shall appoint representatives of sufficient seniority to make strategic
decisions regarding Phase III Clinical Development, approve the Long-Range Plan and Annual Plan and otherwise make final decisions on the sorts of matters likely to come before the JEC on behalf of their respective companies. NN shall designate one
of the members it appoints to be the chairperson of the JEC. If at any time a position on the JEC becomes vacant for any reason, the party that appointed the prior incumbent shall as soon as reasonably practicable appoint a successor. Each party
shall promptly notify the other party of any substitution of another person as its appointee on the JEC. 
 (c) All official
actions, decisions or rulings of the JEC under this Agreement shall be taken by consensus; provided that [*] in the event the [*] after a [*] (generally no more than [*]) and [*]. 
  

 -23- 
 * Confidential Treatment Requested. 

 (d) ZGEN may, in its discretion, withdraw from the JEC at any time, at which time any rights
granted to ZGEN with respect to the JEC under this Article 6 shall cease with immediate effect. 
 6.1.2 Role
and Responsibilities 
 The responsibilities of the JEC shall include: 
 (a) Review and approval of [*] (as defined herein) and [*]. 
 (b) Review of the [*], in particular [*] and [*]. 
 (c) Such other
responsibilities as may be assigned to the JEC pursuant to this Agreement or as may be agreed between the parties from time to time. 
 6.1.3 Meetings and Communications 
 The JEC shall meet face-to-face at least semi-annually at mutually agreed
upon times and locations. Unless otherwise agreed, the location of such meetings will alternate between the parties’ facilities, and the party hosting a meeting shall be responsible for chairing the meeting and secretarial duties (i.e.,
circulating an agenda and taking minutes). Either or both of the parties may, with the consent of the other party (not to be unreasonably withheld), bring other personnel employed by them to meetings of the JEC as observers or to present data and
information. The JEC shall also address issues as they arise in the interim via telephone conference, videoconference or electronic mail. A written agenda for each face-to-face meeting shall be circulated in advance of the meeting by the Alliance
Managers (as defined herein), and written minutes of each meeting shall be taken by the Alliance Managers and shall include the issues discussed, decisions made and action items, if any, arising from the meeting; provided that before adjourning the
JEC shall approve a written (including electronic e.g., PowerPoint slides) summary of all actions taken at a particular meeting. Each face-to-face meeting of the JEC shall conclude with approval of the minutes of prior meetings and of all actions
taken through interim communications since the last face-to-face meeting. Meeting minutes and written summaries of any action taken by way of interim communications shall be promptly submitted by the Alliance Managers: 
 (a) to all members of the JEC; and 
 (b) to the extent such minutes or action involve financial matters, to the Finance Contacts. 
  

	6.2	Development and Commercialization Plan 

 (a) Within one hundred eighty (180) days after the Effective Date, NN shall prepare and provide to ZGEN an initial high-level long-range plan and high-level budget forecast to cover the development
and commercialization of Products for a multi-year period of at least three years consistent with NN’s long-range project and financial planning (such long-range plan and high-level budget, as amended from time to time in accordance with this
subsection (a), the

  

 -24- 
 * Confidential Treatment Requested. 

 
“Long-Range Plan”). Thereafter, NN shall, on an annual basis, prepare and provide to ZGEN updates and amendments to the Long-Range Plan to cover a rolling, multi-year
period of at least three (3) years. Following the formation of a JEC updates to the Long-Range Plan will be submitted to the JEC. 
 (b) Within one hundred eighty (180) days after the Effective Date, NN shall prepare and provide to ZGEN an initial plan and budget to cover in detail the development and commercialization of Products for the remainder of the current
calendar year and the next full calendar year broken out by calendar quarter (such plan and budget, as amended from time to time in accordance with this subsection (b), the “Annual Plan”). Thereafter, NN shall,
on an annual basis, prepare and provide to ZGEN an updated Annual Plan to cover the forthcoming calendar year. Following the formation of a JEC updated Annual Plans will be submitted to the JEC. NN may amend an Annual Plan previously provided to
ZGEN or submitted to the JEC at any time following consultation with ZGEN or at the JEC, as the case may be. 
 (c) The goals of
the Long-Range Plan are (i) the development of Products as required to obtain Regulatory Approval for one or more commercially significant indications as promptly as commercially and technically practicable, (ii) the acquisition of
Regulatory Approval for Product in a manner sufficient to allow the commercialization of Product in those countries of the Territory that represent a commercially reasonable opportunity for NN based on the size of the potential market and other
relevant factors, (iii) the identification, selection and development of additional Products if appropriate and (iv) allow ZGEN to monitor development and make an informed decision regarding an Election to Co-Fund and its participation in
co-promotion in the USA. In addition the Long-Range Plan shall include a summary of marketing, sales, supply and post-approval clinical trial strategies for each Product in the Territory. Following an Election to Co-Fund and so long as ZGEN does not
Opt Out of Co-Funding (i.e., ZGEN is co-promoting Products in the USA or retains the right to do so in the future), each Annual Plan will include a comprehensive market development, marketing, sales, supply, distribution, Phase IV Clinical Trial and
post-approval clinical trial strategy in the USA for each Product for which ZGEN made an Election to Co-Fund. 
  

	6.3	Alliance Managers 

 6.3.1 Appointment 
 Within thirty (30) days following the Effective Date, each of the parties shall appoint
a single individual to act as a single point of contact between the parties to assure the success of their relationship relating to this Agreement (each, an “Alliance Manager”). Each party may change its designated Alliance
Manager from time to time upon written notice to the other party. Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager by written notice to the other party. 
 6.3.2 Responsibilities 
 Each Alliance Manager shall be charged with creating and maintaining a spirit of collaboration between the parties. In addition, each Alliance Manager: 
 (a) will be the point of first referral in all matters of conflict resolution; 
  

 -25- 

 (b) will provide a single point of communication for seeking consensus both internally
within the respective parties’ organizations and between the parties regarding key strategy and plan issues; 
 (c) will
identify and bring disputes to the attention of senior management or, if formed, the JEC in a timely manner; 
 (d) will plan
and coordinate cooperative efforts and internal and external communications; and 
 (e) will take responsibility for ensuring
that governance activities, such as the conduct of required JEC meetings and production of meeting minutes, occur as set forth in this Agreement, and that relevant action items resulting from such meetings are appropriately carried out or otherwise
addressed. 
 Following the formation of the JEC, the Alliance Managers shall use good faith efforts to attend all JEC meetings
and support the chairperson of the JEC in the discharge of his or her responsibilities. Alliance Managers shall be nonvoting participants in JEC meetings. An Alliance Manager may bring any matter to the attention of the JEC if such Alliance Manager
reasonably believes that such matter warrants such attention. 
  

	6.4	Finance Contacts 

 (a)
Each party shall appoint its initial finance contact (each a “Finance Contact”) within thirty (30) days following the Effective Date and shall promptly thereafter notify the other party of such appointment. Each Finance
Contact shall consult with the other regarding accounting policies and practices relevant to this Agreement and otherwise support the Alliance Managers and, if formed, the JEC. If at any time a vacancy occurs for any reason, the party that appointed
the prior incumbent shall as soon as reasonably practicable appoint a successor. Each party shall promptly notify the other party in writing of any substitution of another person as its Finance Contact. 
 (b) Each party’s Finance Contact will be available throughout the term of this Agreement to answer any reasonable questions from the
other party’s Finance Contact. 
 ARTICLE SEVEN 
 Confidentiality 
  

	7.1	Confidential Information 

 For the purposes of this Agreement, “Confidential Information” shall include all proprietary information and materials, patentable or otherwise, of a party that is disclosed by or on behalf of such disclosing party
to the receiving party, including DNA sequences, amino acid sequences, vectors, cells, substances, formulations, techniques, methodology, equipment, data, reports, know-how, assay results, preclinical studies and clinical trials and the results
thereof, patent positioning and business plans, including any negative developments. 
  

 -26- 

	7.2	Confidentiality Obligation 

 Except as otherwise authorized under this Agreement, during the term of this Agreement and for a period of five (5) years thereafter, each party shall maintain as secret and confidential all Confidential Information obtained from the
other party pursuant to this Agreement or a Prior Agreement or prior to and in contemplation of this Agreement or a Prior Agreement. Each party shall respect the other party’s proprietary rights in such Confidential Information, use the same
exclusively for the purposes of this Agreement, and disclose the same only to those of its representatives to whom and to the extent that such disclosure is reasonably necessary for the purposes of this Agreement. The obligations under this
Section 7.2 shall survive the termination of this Agreement. Subject to Section 10.9, upon termination or expiration of this Agreement, each party shall, upon request of the other party, promptly return and
destroy all documents and document copies containing Confidential Information belonging to such other party, provided that each party may retain one copy of such Confidential Information for the sole purpose of ensuring compliance with this
Article Seven.  
  

	7.3	Release from Confidentiality Obligation 

 Notwithstanding the foregoing provision, a party shall be permitted to disclose any Confidential Information of the other party to (i) its Affiliates, Commercialization Partners, Sublicensees and
lenders, (ii) prospective Affiliates, Commercialization Partners, Sublicensees and lenders and (iii) its licensors under third party agreements related to IL-21 Embodiments, (iv) its legal advisors, in particular patent practitioners
and (v) its auditors, who are, in the case of each of subsections (i)-(v), subject to written confidentiality and non-use restrictions at least as stringent as those contained herein. Notwithstanding the above, a party shall be
permitted to disclose the [*]. The confidentiality and non-use restrictions imposed on [*] shall be [*] that [*]. The party disclosing Confidential Information to [*] or to [*] shall [*] the Confidential Information is disclosed and the [*]. In
addition, a party shall be permitted to disclose any Confidential Information of the other party to any patent office in any country, as is reasonably required for filing or prosecuting any patent application permitted to be filed by it hereunder.
Furthermore, the obligations of Section 7.2 shall not apply to Confidential Information that: 
 (a) was
properly in the possession of the receiving party, without any restriction on use or disclosure, prior to receipt from the disclosing party, and such possession can be demonstrated by competent evidence of the receiving party; 
 (b) is in the public domain by public use, publication, general knowledge or the like, or after disclosure hereunder becomes general or
public knowledge through no fault of the receiving party; 
 (c) is properly obtained by the receiving party from a third party
not under a confidentiality obligation; 
  

 -27- 
 * Confidential Treatment Requested. 

 (d) is independently developed by or on behalf of the receiving party without the assistance
of the Confidential Information of the disclosing party; or 
 (e) is required to be disclosed by order of any court or
governmental or regulatory authority after notification to the disclosing party of the necessity to allow the disclosing party to seek protection for the disclosing party’s Confidential Information from such court or governmental or regulatory
authority. 
 ARTICLE EIGHT 
 Indemnification 
  

	8.1	Personal Injury or Property Damage 

 (a) NN shall indemnify, defend and hold harmless ZGEN, its directors, officers, employees and agents (collectively, the “Indemnitees”) from and against any and all claims,
judgments, costs, awards, expenses (including any attorneys’ fees) or liability of any kind arising out of personal injury or property damage caused or alleged to be caused by any Product developed, manufactured, used or sold by NN or any of
its Affiliates, Commercialization Partners or Sublicensees or the use of any IL-21 Related Patents or IL-21 Related Know-How by NN or any of its Affiliates, Commercialization Partners or Sublicensees. In addition, NN shall assume all obligations for
warranties and product liability claims that accompany or result from the sale or use of any Product developed, manufactured or sold by NN or any of its Affiliates, Commercialization Partners or Sublicensees and shall indemnify, defend and hold
harmless the Indemnitees from and against any and all claims, judgments, costs, awards, expenses (including any attorneys’ fees) or liability of any kind arising from customers’ or users’ use of any Product developed, manufactured or
sold by NN or any of its Affiliates, Commercialization Partners or Sublicensees and relating to such warranty obligations or product liability claims. 
 (b) NN’s obligations under this Section 8.1 shall not apply to any Indemnitee to the extent that (i) such Indemnitee is grossly negligent or engaged in willful misconduct or
(ii) such claims arise from any material breach by the Indemnitees of any of their representations, warranties or obligations under this Agreement. 
 (c) ZGEN shall (i) promptly notify NN of any claim, judgment, cost, award or expense covered by this Section 8.1, (ii) reasonably cooperate with NN in the defense of such
claim, judgment, cost, award or expense, at NN’s cost and expense in connection therewith, (iii) allow NN to control the defense of the claim, judgment, cost, award or expense, and (iv) not compromise or settle the claim, judgment,
cost, award or expense without NN’s prior written consent, which consent shall not be unreasonably withheld. 
  

	8.2	Insurance 

 NN shall use
commercially reasonable efforts to maintain and cause its Affiliates, Commercialization Partners and Sublicensees to maintain appropriate product liability insurance with respect to development, manufacture and sale of Products in such amount as NN
customarily maintains with respect to its other products. NN shall use commercially reasonable

  

 -28- 

 
efforts to maintain and cause its Affiliates, Commercialization Partners and Sublicensees to maintain such insurance for so long as it continues to manufacture or sell Products, and thereafter
for so long as NN customarily maintains insurance with respect to sales of its other products. 
 ARTICLE NINE 

Patents 
  

	9.1	Prosecution 

 ZGEN shall
be solely responsible, as it shall determine, for the filing and prosecution of any and all patent applications included in the IL-21 Related Patents (including opposition and interference proceedings) and for the maintenance of any patents included
in the IL-21 Related Patents. NN shall reimburse ZGEN within thirty (30) days after date of invoice for all of ZGEN’s out-of-pocket costs for the IL-21 Related Patents incurred after the Effective Date, including translation costs, filing
and maintenance fees, and costs of oppositions and interferences, outside attorneys’ and expert fees. ZGEN will in September of each year provide NN with an estimate of reasonable out-of-pocket costs for the IL-21 Related Patents for the
following year. 
 Notwithstanding the above, with at least sixty (60) days written notice to ZGEN, NN may elect to
discontinue reimbursing ZGEN’s out-of-pocket costs for a specified patent application or patent within the IL-21 Related Patents, in which case ZGEN may choose to maintain such patent or patent application at its own expense and such patent
application or patent shall no longer continue to be considered part of the IL-21 Related Patents and the license granted by ZGEN to NN pursuant to Section 2.1; provided, (i) if the patent application or patent NN
elects to discontinue reimbursing ZGEN’s out-of-pocket costs for is a patent or patent application in one or more of the countries set forth in Appendix 5 then for such country(ies) such patent or patent application shall continue
to be considered an IL-21 Related Patent for the purposes of Section 10.6; and (ii) if NN elects to discontinue reimbursing ZGEN’s out-of-pocket costs for any patent or patent application in a country not listed in
Appendix 5, then for such country such patent or patent application shall not be considered an IL-21 Related Patent for the purposes of Section 10.6. 
 ZGEN shall deliver to NN a copy of each new patent application within the IL-21 Related Patents and all documents received from patent
offices regarding the IL-21 Related Patents. As long as NN is not in material breach of any obligation hereunder, and provided NN has continued to pay ZGEN’s out-of-pocket costs for the IL-21 Related Patents in accordance with this
Section 9.1: (a) NN shall have the right to review and comment on the nature and text of such, and ZGEN shall consider in good faith any comments from NN regarding steps that might be taken to strengthen the IL-21 Related
Patents, provided that all final decisions regarding the filing and prosecution of IL-21 Related Patents shall be within ZGEN’s sole discretion; and (b) if ZGEN elects not to prosecute or maintain any IL-21 Related Patents in any country
in the Territory, ZGEN shall provide NN with written notice of such election, in which case, NN shall be entitled to assume responsibility for prosecuting or maintaining such IL-21 Related Patent at its expense, in ZGEN’s name. Upon NN’s
reasonable request and at no out-of-pocket expense to ZGEN, ZGEN shall render such reasonable assistance, execute any documents and do such other acts as may be reasonably necessary in connection with such prosecution or maintenance of any such
IL-21 Related Patents by NN. 
  

 -29- 

 For the avoidance of doubt, the ZGEN patent application family 02-11 previously licensed to
NN (International Application PCT US/03/17808 titled ‘USE OF ZALPHA11 LIGAND IN CANCER AND OTHER THERAPEUTIC APPLICATIONS’ filed June 6, 2003 and foreign equivalents thereof including US parent patent application 10/456,262) (the
“02-11 Patents”) is related to the IL-21 Protein and is excluded from this Agreement. Notwithstanding the preceding sentence, if any claims to IL-21 Antagonist Proteins were to issue from the 02-11 Patents, they
would be included in the licenses and reservations pursuant to Article Two as they relate to an IL-21 Antagonist Protein. 
  

	9.2	Patent Term Extension 

 NN
shall provide written notice to ZGEN within ten (10) days after receiving (i) Regulatory Approval by any Agency to market any Product or (ii) any other governmental approval obtained by or on behalf of NN, any Affiliate,
Commercialization Partner or Sublicensee that is pertinent to any patent term extension (including supplementary protection certificates) for any IL-21 Related Patent. Subject to this Section 9.2, NN shall have the right to seek,
or, where appropriate, to direct ZGEN to seek, an extension of the term of any IL-21 Related Patent for a licensed Product (including filing for patent term restoration under the U.S. Patent Statutes (35 U.S.C §§1-376) and seeking
supplementary protection certificates in the member states of the European Union or European Economic Area, or Switzerland); provided, that the parties shall follow the procedure described below on a Product-by-Product and country-by-country basis:

 (a) At least nine (9) months prior to an anticipated Regulatory Approval the Patent Contacts (as defined in
Section 9.7) shall confer and discuss in good faith the IL-21 Related Patents as well as any patent Controlled by NN (a “NN Patent”) eligible for extension for the Product in the given
jurisdiction where the Regulatory Approval is sought. 
 (b) Within two (2) months of the conference in
Section 9.2(a) the Patent Contacts shall mutually agree in writing upon (i) a recommendation as to which patent(s) to extend in such jurisdiction, (ii) the preferred patent to select providing such extension is
ultimately granted including the party responsible for applying for such extensions, and (iii) the general identification of the documents necessary from each party that will be necessary to support such extension. 
 (c) Subject to Section 9.2(e) below, if the Patent Contacts cannot mutually agree in accordance to
Section 9.2(b) above as to which patent(s) to extend in a jurisdiction, then within three (3) months of the conference in Section 9.2(a) [*] with regard to which patent(s) to extend in such jurisdiction,
and the [*] providing such extension is ultimately granted [*]. Exercise of the [*] shall be effective upon receipt of written notice of exercise from NN to ZGEN, within three (3) months of the conference in Section 9.2(a) or
shall expire on the last day of such three month period (“[*] Option Period”). 
  

 -30- 
 * Confidential Treatment Requested. 

 (d) The parties shall cooperate with any efforts to seek patent term extension of an IL-21
Related Patent or a NN Patent, including diligently supplying all pertinent information pertaining to such patent term extension, and with all information and supporting documents required to comply with all laws pertaining to the extension of such
patent term. 
 (e) If NN by exercise of its [*] elects to extend an IL-21 Related Patent and ZGEN reasonably believes that
extension of such an IL-21 Related Patent would conflict with or otherwise interfere with the ability of ZGEN or its commercialization partners, licensees, or affiliates to extend such IL-21 Related Patent based upon anticipated Regulatory Approval
of an IL-21 Protein in such jurisdiction, then ZGEN shall provide NN with written notice of such interference within two weeks of receipt of NN’s written notice of exercise of NN’s [*] and immediately upon receipt of ZGEN’s written
notice, NN shall no longer be able to select such IL-21 Related Patent with NN’s [*] in Section 9.2(c) with regard to such identified patent for such Product in such jurisdiction. NN shall then have two weeks from receipt of
ZGEN’s written notice to use its [*] to select a different patent to extend for such Product in such jurisdiction. 
 For
the avoidance of doubt with respect to this Section 9.2, regardless of the period for which the term of any IL-21 Related Patent is extended in a country, NN shall continue to pay royalties on a Patent Product pursuant to
Section 4.1 or 5.3.2 on Net Sales of the Patent Product in such country through the expiration date of the last-to-expire IL-21 Related Patent with a Valid Claim in such country which would be infringed, in the
absence of the license granted under this Agreement, by the making, using, importation, exportation, offer for sale, or sale of the Patent Product in such country. 
 For the avoidance of doubt, NN shall not pay royalties on a Patent Product for Net Sales of such Patent Product in such country for the period by which the extended term of any NN Patent in such country
extends beyond the term of the last-to-expire IL-21 Related Patent with a Valid Claim in such country which would be infringed, in the absence of the license granted under this Agreement, by the making, using, importation, exportation, offer for
sale, or sale of the Patent Product in such country. 
  

	9.3	Notice of Infringement and Conference 

 Each party shall promptly notify the other party in writing of any alleged or threatened infringement, in the Territory of any IL-21 Related Patent. Any notice provided under this
Section 9.3 shall set forth all relevant facts (to the extent known by the party giving notice) in reasonable detail and shall include a reasonable description of available evidence associated therewith or copies of any readily
available documentary evidence associated therewith. Upon receipt of such written notice, the parties shall confer regarding all available evidence of infringement or attack, and the manner of addressing such infringement or attack. The parties may
agree to pursue the matter jointly. 
  

	9.4	ZGEN Has First Right 

 Unless the parties agree otherwise, ZGEN shall have the first right, but not the obligation, to initiate and control any action, including cease and desist letters and lawsuits, at its expense, to

  

 -31- 
 * Confidential Treatment Requested. 

 
enforce the IL-21 Related Patents against any infringer or alleged infringer of the IL-21 Related Patents to the extent exclusively licensed hereunder to NN. ZGEN shall notify NN of ZGEN’s
decisions regarding such infringement, and shall keep NN reasonably apprised of the progress of the matter. As long as NN is not in material breach of any obligation hereunder, NN shall have the right, at its own expense, to join any legal
proceeding initiated by ZGEN regarding any IL-21 Related Patent in the Territory that is being infringed; it is understood, however, that ZGEN shall have sole control over any issues or matters pertaining to the validity or scope of any and all
IL-21 Related Patents. Unless NN joins such suit, as described above, ZGEN shall have the right to retain all damages awarded. If NN does join such suit, then out of any damages awarded, the parties have an equal right to recover their expenses for
the proceeding; then NN shall be entitled to retain all damages specifically awarded by the court to NN, e.g., lost profits; then ZGEN shall have the right to retain any damages remaining. 
  

	9.5	NN Has Secondary Right 

 If within sixty (60) days after the conference described in Section 9.3, ZGEN has not taken any action to stop such infringement, and as long as NN is not in material breach of any obligation hereunder, NN shall have
the right to take legal action regarding any infringement, at its own expense. If NN initiates legal proceedings hereunder, ZGEN shall have the right to join such suit, at its own expense. If the law governing any proceeding brought by NN under this
Section 9.5 requires ZGEN to join such proceeding, then ZGEN shall be represented by NN’s legal counsel, at NN’s expense. If NN’s counsel is unable to represent ZGEN because of a bona fide conflict of interest, then
ZGEN may engage other competent legal counsel, reasonably acceptable to NN, to represent ZGEN in such proceeding, at NN’s expense. If ZGEN elects not to use NN’s counsel for any reason other than a bona fide conflict of interest, then ZGEN
may engage competent legal counsel of its own choosing, at ZGEN’s expense. If NN unilaterally elects to discontinue any proceeding instituted under this Section 9.5 (other than as part of a settlement), NN shall give ZGEN
reasonable prior notice of such election. ZGEN may elect to continue such proceedings in its sole name, under its sole control, and at its own expense; if ZGEN so elects, NN shall reasonably cooperate, at no out-of-pocket expense to NN, in all
actions reasonably necessary to transfer control of the proceedings from NN to ZGEN. NN shall indemnify, defend and hold harmless ZGEN and the Indemnitees (as defined in Section 8.1) from any and all claims, damages or other
obligations arising out of or resulting from any claim or legal proceedings instituted by NN under this Section 9.5; provided that the foregoing indemnity shall not apply to the extent ZGEN incurs claims, damages or obligations
because ZGEN elected to continue the proceedings in its own name as described above. Unless ZGEN voluntarily joins such suit, as described above, NN shall have the right to retain all damages awarded. If ZGEN does voluntarily join such suit, then
out of any damages awarded, the parties have an equal right to recover their expenses for the proceeding; then NN shall pay to ZGEN the amount that would have been payable as royalties hereunder if the infringer’s infringing activities had been
those of NN; then NN shall have the right to retain any damages remaining. If ZGEN does not voluntarily join such suit and in the event that it is an indispensable party required to be joined as a party in such infringement action involving the NN,
ZGEN hereby agrees to waive any objections to such joinder on the grounds of standing, personal jurisdiction, venue and/or forum non conveniens, provided NN shall promptly reimburse ZGEN for all costs associated with such joinder. 
  

 -32- 

	9.6	Settlement 

 (a) ZGEN may
enter into any settlement, consent judgment, or other voluntary final disposition of any action that was initiated by ZGEN in accordance with Section 9.4 without NN’s prior consent; provided that NN receives a general release
of any claims against it in such proceeding and NN is promptly provided thereafter a copy of such settlement, consent judgment or other voluntary disposition and such settlement is not otherwise inconsistent with the terms of this Agreement and
would not have a material adverse impact on the validity, scope or enforceability of the IL-21 Related Patents, or result in a material payment by NN to a third party. Any other settlement, consent judgment or voluntary final disposition of any
proceeding by ZGEN shall require the prior written consent of NN. 
 (b) NN may enter into any settlement, consent judgment, or
other voluntary final disposition of any action that was initiated by NN in accordance with Section 9.5 without ZGEN’s prior consent; provided that ZGEN receives a general release of any claims against it in such proceeding
and ZGEN is promptly provided thereafter a copy of such settlement, consent judgment or other voluntary disposition and such settlement is not otherwise inconsistent with the terms of this Agreement and would not have a material adverse impact on
the validity, scope or enforceability of the IL-21 Related Patents, or result in a material payment by ZGEN to a third party, or, following the date of such settlement, result in a material reduction in payments by NN to ZGEN pursuant to
Article Four. Any other such settlement, consent judgment or voluntary final disposition of any proceeding by NN shall require the prior written consent of ZGEN. 
  

	9.7	Patent Contacts 

 (a) Each
party shall appoint its initial patent contact to coordinate patent matters in accordance with this Article Nine (each a “Patent Contact”) within thirty (30) days following the Effective Date
and shall promptly thereafter notify the other party of such appointment. If at any time a vacancy occurs for any reason, the party that appointed the prior incumbent shall as soon as reasonably practicable appoint a successor. Each party shall
promptly notify the other party in writing of any substitution of another person as its Patent Contact. 
 (b) Each party’s
Patent Contact will be available throughout the term of this Agreement to answer any reasonable questions from the other party’s Patent Contact. 
  

	9.8	Cooperation 

 In any legal
proceeding conducted under this Article Nine, each party agrees, without charge, to render such reasonable assistance, execute any documents and do such other acts as may be reasonably necessary in such legal action as the other party
may reasonably request. 
  

 -33- 

	9.9	Affiliates, Commercialization Partners and Sublicensees 

 NN shall require its Affiliates, Commercialization Partners and Sublicensees to comply with this Article Nine.  
  

	9.10	Filing, Prosecution, Maintenance of Cell Line Patents and Construction Strain Patents 

 ZGEN shall be solely responsible at its sole cost and expense for the filing, prosecution, maintenance and enforcement of Cell Line Patents
and Construction Strain Patents. 
  

	9.11	Filing, Prosecution, Maintenance of Patents and Patent Applications arising from Work Performed pursuant to Annual Plan or Long Range Plan

 As among the parties, all intellectual property arising from work performed pursuant to any Annual Plan or
Long-Range Plan during the term of this Agreement shall be owned by NN or, if owned by ZGEN or jointly owned by ZGEN and NN, shall be licensed to NN in accordance with this Agreement. NN shall be solely responsible at its sole cost and expense for
the filing, prosecution, maintenance and enforcement of all such intellectual property regardless of ownership. Ownership of intellectual property arising from work performed pursuant to any Annual Plan or Long-Range Plan during the term of this
Agreement shall be determined in good faith in accordance with a determination of inventorship pursuant to the United States patent laws (Title 35, United States Code). All determinations of such inventorship shall be documented to ensure that
divisional or continuation patent applications reflect appropriate inventorship. 
 ARTICLE TEN 
 Term and Termination 
  

	10.1	Term and Expiration 

 This
Agreement and the licenses contained herein shall come into force on the Effective Date. Unless terminated earlier, the licenses provided hereunder for any Products shall expire on a country-by-country basis on the date on which ZGEN is no longer
entitled to receive a royalty with respect thereto, and this Agreement shall expire on the date on which ZGEN is no longer entitled to receive a royalty from NN on any Product under this Agreement. After expiration (but not termination), NN shall
have a fully paid-up (except for payments to third parties pursuant to Section 4.4), irrevocable, non-exclusive license under the IL-21 Related Know-How to make, have made, use, sell, offer to sell and import Know-How Products in
the Territory. 
  

	10.2	Termination by NN for Convenience 

 NN may terminate this Agreement for any reason by giving ZGEN [*] prior written notice. 
  

 -34- 
 * Confidential Treatment Requested. 

	10.3	Safety Reasons 

 NN may
terminate this Agreement and the licenses granted hereunder upon six (6) months prior written notice to ZGEN with an explanation contained therein if, in the reasonable opinion of NN senior management, the development and/or commercialization
of IL-21 Embodiments must be terminated for Safety Reasons. In such event, NN shall be obligated to pay to ZGEN all Milestone Fees outlined in Section 3.2 that have been achieved and accrued under this Agreement prior to
termination. For purposes of this Section 10.3, “Safety Reasons” means [*], based on [*], that there [*] at [*] of the [*] or, if [*], [*] of the [*] listed in [*] in the [*] for which [*].

 If NN terminates this Agreement pursuant to this Section 10.3, then any license granted to ZGEN under
Section 10.9(c), any obligation of NN to continue to supply a Product under Section 10.9(d) and any obligation to assign to ZGEN any IND, BLA or Regulatory Approval under Section 10.9(b) shall
be of no force or effect. 
  

	10.4	Insolvency 

 Either party
shall have the right to terminate this Agreement forthwith by written notice to the other party (a) if the other party is declared insolvent or bankrupt by a court of competent jurisdiction, (b) if a voluntary or involuntary petition in
bankruptcy is filed in any court of competent jurisdiction against the other party and such petition remains undismissed, undischarged or unbonded for a period of ninety (90) days after the filing thereof, or (c) if the other party shall
make or execute an assignment for the benefit of creditors generally, have a receiver, administrator or an equivalent official appointed with respect to its properties or undertakings, enter into any liquidation or become insolvent. All rights and
licenses granted under or pursuant to this Agreement by ZGEN to NN are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, as amended, (“Bankruptcy
Code”) licenses of right to “intellectual property” as defined under Section 101 of the Bankruptcy Code. The parties agree that NN, as licensee of such rights under this Agreement, shall retain and may fully exercise all
of its rights and elections under the Bankruptcy Code. The parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against ZGEN under the Bankruptcy Code, NN shall be entitled to a complete duplicate of (or
complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, shall be promptly delivered to NN (i) upon any such commencement of a bankruptcy proceeding upon NN’s written request
therefor, unless ZGEN elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under (i) above, following the rejection of this Agreement by or on behalf of the party subject to such proceeding
upon written request therefor by the non-subject party. 
  

	10.5	Breach 

 Each party shall
have the right to terminate this Agreement after written notice to the other party in the event the other party is in material breach of this Agreement (including failure to meet diligence obligations or timely pay any amounts due hereunder), unless
the other party cures such breach within sixty (60) days (or ten (10) days in the case of the failure to pay any

  

 -35- 
 * Confidential Treatment Requested. 

 
amount due) after the date of notice; provided, however, that any termination shall not release either party from any obligations accrued prior thereto. Upon termination of this Agreement by NN
pursuant to this Section 10.5, NN shall be entitled, at its own cost and for its own benefit, to sell or otherwise dispose of all Product that it has on hand on the effective date of termination during the six (6) months
following the effective date of termination; provided that all such sales shall bear royalties in accordance with this Agreement. 
  

	10.6	Termination of License With Respect to Contested Patent Rights 

 ZGEN may at its option terminate this Agreement to the extent NN, or its Affiliate, Commercialization Partner or Sublicensee, or any entity acting in concert with or on behalf of any of them, commences
any action or asserts any formal position in any forum (including a court, a patent office, or an arbitral tribunal, and whether in the form of petitions for declaratory relief, claims, counterclaims, defenses, interferences, petitions for
re-examination, oppositions, or otherwise) that any IL-21 Related Patent is invalid or unenforceable. 
  

	10.7	Effect of Expiration or Termination 

 Expiration or termination of this Agreement shall not relieve the parties of any obligations accruing prior to such expiration or termination. In addition to any provision that expressly provides for its
survival, any accrued obligation and the provisions of Article One, Section 2.3(b), Section 4.7, Articles Seven and Eight, Section 10.3, 10.8, 10.9,
and Articles Eleven and Twelve shall survive the expiration or termination of this Agreement. Expiration or termination shall not affect any party’s ability to seek any other remedies available at law.

  

	10.8	Survival of Obligations under Second Restated License Agreement 

 Any obligations accrued under the Second Restated License Agreement shall survive in accordance with the terms set forth in the Second Restated License Agreement. For the avoidance of doubt, obligations
that NN has accrued regarding payment of costs accrued for IL-21 Related Patents as defined in the Second Restated License Agreement shall be payable in accordance with the terms set forth in this Agreement i.e., such costs shall rollover.

  

	10.9	Return of Project Following Termination 

 Upon termination of this Agreement by NN pursuant to Section 10.2 and upon any termination of this Agreement by ZGEN, NN shall: 
 (a) At ZGEN’s request, transfer to ZGEN as promptly as is reasonably practicable, at no cost to ZGEN, all material data relating to
Products that (i) is Controlled by NN or its Affiliates, (ii) has not previously been transferred to ZGEN, and (iii) was generated in the performance of activities by or on behalf of NN or its Affiliates, Commercialization Partners or
Sublicensees under this Agreement or a Prior Agreement. During the [*] period commencing on the effective date of termination, NN shall offer, at no cost to ZGEN, such assistance as ZGEN may reasonably request in connection with the transfer of such
data. If NN identifies any such data to ZGEN in writing and ZGEN does not request the transfer of an item of data in accordance

  

 -36- 
 * Confidential Treatment Requested. 

 
with this Section 10.9(a) within [*] days following the date on which NN identifies such data in writing to ZGEN, NN shall be entitled to destroy such data at its own cost if
permitted to do so under applicable law. 
 (b) At ZGEN’s request, assign to ZGEN all INDs, BLAs and Regulatory Approvals
and, to the extent assignable, contracts for the manufacture, distribution or sale of Products. 
 (c) At ZGEN’s request,
NN shall and does hereby grant to ZGEN an exclusive license, with right to sublicense, under the NN Development Technology (including NN Patents) that is necessary to make, have made, use, sell, offer to sell and import Products in the Territory.

 (d) At ZGEN’s request, supply Products to ZGEN pursuant to a manufacturing and supply agreement, including costs and
delivery terms, to be negotiated by the parties in good faith promptly following the date the notice of termination was given, the period for such manufacture and supply to be, unless the parties otherwise agree, the shorter of (i) a period of
[*] years from the effective date of termination, or (ii) until ZGEN has the ability to manufacture the applicable Product in compliance with the Regulatory Approvals therefor and applicable laws following a technology transfer of manufacturing
operations for such Product to ZGEN in accordance with terms and conditions to be negotiated by the parties in good faith promptly following the date the notice of termination was given. 
 ARTICLE ELEVEN 
 Representations and Warranties 

  

	11.1	Representations, Warranties and Covenants of NN 

 As of the Effective Date, NN represents and warrants to and covenants with ZGEN that: 
 (a) NN is a corporation duly organized, validly existing and in corporate good standing under the laws of Denmark; and 
 (b) NN has the corporate and legal right, title, authority and power to enter into this Agreement; and 
 (c) NN has
taken all necessary action to authorize the execution, delivery and performance of this Agreement; and 
 (d) upon the execution
and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of NN, enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium
or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity
or at law); and 
 (e) the performance of its obligations under this Agreement will not conflict with or result in a breach of
any agreements, contracts or other arrangements to which it is a party; and 
  

 -37- 
 * Confidential Treatment Requested. 

 (f) NN will not during the term of this Agreement enter into any agreements, contracts or
other arrangements that would prevent NN from meeting its obligations or adversely impact ZGEN’s rights under this Agreement; and 
 (g) NN will comply with all applicable laws, regulations and guidelines in connection with the exercise of NN’s license rights under this Agreement, including all applicable product safety, product testing, product labeling, package
marking and product advertising laws and regulations and the regulations of any relevant nations concerning any export or other transfer of technology, services or products. 
  

	11.2	Representations, Warranties and Covenants of ZGEN 

 As of the Effective Date, ZGEN represents and warrants to and covenants with NN that: 
 (a) ZGEN is a corporation duly organized, validly existing and in corporate good standing under the laws of the State of Washington, USA; and 
 (b) ZGEN has the corporate and legal right, title, authority and power to enter into this Agreement; and 
 (c) ZGEN has taken all necessary action to authorize the execution, delivery and performance of this Agreement; and 
 (d) upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of ZGEN enforceable in accordance with its terms, except as enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless
of whether such enforceability is considered in a proceeding in equity or, at law); and 
 (e) the performance of its
obligations under this Agreement will not conflict with or result in a breach of any agreements, contracts or other arrangements to which it is a party; and 
 (f) ZGEN will not after the Original License Effective Date enter into any agreements, contracts or other arrangements that would prevent ZGEN from meeting its obligations or adversely impact NN’s
rights under this Agreement; 
 (g) ZGEN will comply with all applicable laws, regulations and guidelines in connection with the
performance of ZGEN’s obligations under this Agreement; 
 (h) Part A of Appendix 1 identifies all patent
applications and patents in the Territory that are owned or Controlled by ZGEN that claim an invention with a date of conception prior to the Effective Date and that claim: (i) an IL-21 Embodiment; (ii) a process, formulation and/or
mixture comprising an IL-21 Embodiment; (iii) a method of making or manufacturing an IL-21 Embodiment; or (iv) a method of using an IL-21 Embodiment; 
  

 -38- 

 (i) other than the [*] Agreement, there are no agreements or arrangements between ZGEN and
any third party relating to the IL-21 Related Patents or which could otherwise affect NN’s ability to market or sell Products in the Territory; 
 (j) ZGEN has not received any written communications from any third party that any patent within the IL-21 Related Patents is invalid or unenforceable or, except in connection with the ongoing opposition
proceedings related to [*], that any patent application or patent within the IL-21 Related Patents is subject to interference, reexamination, reissue, revocation, opposition, appeal or other administrative proceedings (including any third party
inventorship dispute); provided that nothing in this Agreement shall be construed as a representation or warranty as to the scope or validity of any patent application or patent within the IL-21 Related Patents; 
 (k) all required maintenance fees have been paid with regard to the IL-21 Related Patents; and 
 (l) following execution of the Letter Agreement, ZGEN is not in breach or default of any of its material obligations under the [*]
Agreement. 
  

	11.3	Warranty Disclaimer 

 EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO IL-21 EMBODIMENTS, PRODUCTS, IL-21 RELATED PATENTS, IL-21 RELATED KNOW-HOW OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY
DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT AND PATENTABILITY WITH RESPECT TO ANY AND ALL OF THE FOREGOING. 
  

	11.4	Limited Liability 

 EXCEPT
IN THE CASE OF GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, NEITHER NN NOR ZGEN WILL BE LIABLE WITH RESPECT TO ANY MATTER ARISING UNDER THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY PUNITIVE OR
EXEMPLARY DAMAGES. 
 ARTICLE TWELVE 
 Miscellaneous 
  

	12.1	Assignment 

 This
Agreement may not be assigned by either party without prior written consent of the other party, except to: (a) a successor or a purchaser of all or substantially all of the party’s assets and business or (b) an Affiliate; provided,
however, that in the event of an assignment by NN to an Affiliate, the Affiliate’s rights under this Agreement shall terminate once it ceases being an Affiliate of NN (however, its rights may be reassigned back to NN at the time it ceases being
an

  

 -39- 
 * Confidential Treatment Requested. 

 
Affiliate of NN). If, as a result of any assignment of any rights or interest in this Agreement by NN, any payment by or on behalf of NN to ZGEN is subject to an increased level of tax
withholding than would have been the case under this Agreement with payments by NN from Denmark and ZGEN cannot use any related tax credit as an offset against its obligation to pay United States federal income tax in the year in which the
withholding is effected, NN shall pay ZGEN an amount such that, after deduction of any amount required to be withheld, ZGEN receives the same amount that it would have received but for the assignment. In the event of any permissible assignment under
this Agreement, the assignor shall guarantee the assignee’s performance of the assignor’s obligations hereunder. ZGEN shall have the right to assign its right to receive any payments under this Agreement. 
  

	12.2	Relationship between the Parties 

 Nothing in this Agreement is intended to create or shall be deemed to constitute a partnership, agency or joint venture relationship between the parties or their sublicensees, contractors or licensees. Neither party shall be responsible for
the acts or omissions of the other party, and neither party shall have the authority to speak for, represent or obligate the other party in any way without the prior written authority of the other party. 
  

	12.3	Public Announcements 

 (a)
The parties will issue a joint press release, substantially in the form set out in Schedule 2, and will cooperate in the release thereof as soon as practicable after the signature of this Agreement by the parties. 
 (b) No other public announcement or other disclosure to third parties (other than as permitted by Section 7.3) concerning
the existence or terms of this Agreement shall be made, either directly or indirectly, by either party hereto, without first obtaining the written approval of the other party, which shall include agreement upon the nature and text of such
announcement or disclosure, except as may be required by any applicable law or regulation, including those of the U.S. Securities and Exchange Commission. The party desiring to make any such public announcement or other disclosure shall inform the
other party of the proposed announcement or disclosure by providing the other party with a written copy thereof, and allowing reasonably sufficient time prior to public release to permit such other party to comment upon such announcement or
disclosure. Once any such public announcement or disclosure has been approved in accordance with this Section 12.3, then either party may appropriately communicate information contained in such permitted announcement or
disclosure. 
 (c) Each party agrees that it shall reasonably cooperate with the other with respect to all disclosures regarding
this Agreement to the Securities and Exchange Commission and any other governmental or Agencies, including requests for confidential treatment of proprietary information of either party included in any such disclosure. 
  

 -40- 

	12.4	Use of Names, Trade Names and Trademarks 

 Except as provided herein, nothing contained in this Agreement shall be construed as conferring any right on either party to use in advertising, publicity or other promotional activities any name, trade
name, trademark or other designation of the other party hereto, including any contraction, abbreviation or simulation of any of the foregoing, unless the express written permission of such other party has been obtained. 
  

	12.5	Force Majeure 

 If either
party to this Agreement is prevented or delayed in the performance of any of its obligations under this Agreement by force majeure, and if such party gives written notice thereof to the other party specifying the matters constituting force majeure,
together with such evidence as it can reasonably give and specifying the period for which it is estimated that such prevention or delay will continue, then the party in question shall be excused from the performance of its obligations or the
punctual performance thereof as the case may be as from the date of such notice for so long as such cause of prevention or delay shall continue. For the purpose of this Agreement, “force majeure” shall be deemed
to be any cause affecting the performance of this Agreement arising from or attributable to acts, events, omissions or accidents beyond the reasonable control of the party. 
  

	12.6	Governing Law 

 This
Agreement shall be governed by and construed in accordance with the law of the State of New York, without regard to the conflicts of law rules of such state. 
  

	12.7	Waiver of Remedies 

 No
forbearance, delay or indulgence by either party in enforcing the provisions of this Agreement shall prejudice or restrict the rights of that party, nor shall any waiver of its rights operate as a waiver of any subsequent breach, and no right, power
or remedy herein conferred upon or reserved for either party is exclusive of any other right, power or remedy available to that party. 
  

	12.8	Entire Agreement 

 This
Agreement and the Appendices hereto constitute the entire agreement between the parties and supersede all prior oral and written agreements, understandings or arrangements relating to the subject matter hereof, including the Second Restated License
Agreement and Confidentiality Agreement, dated January 15, 2008. No addition to or modification of any provision of this Agreement shall be binding upon the parties, unless made in writing and signed by a duly authorized representative of each
of the parties. 
  

 -41- 

	12.9	Notices 

 All notices or
other communication hereunder shall be in writing and shall be deemed to have been duly given if delivered personally, faxed with receipt acknowledged (and with a confirmation copy also sent by registered mail, return receipt requested), or
delivered by a recognized commercial courier service with receipt acknowledged, postage prepaid, as follows: 
  

					
	If to NN:	  	Novo Nordisk A/S
		  	Novo Allé
		  	DK-2880 Bagsvaerd
		  	Denmark
		  	Attn: Head of Business Development
		  	Facsimile:	  	+45 4442-1830
		
	With a copy to:	  	Novo Nordisk Legal Department
		  	Novo Allé
		  	DK-2880 Bagsvaerd
		  	Denmark
		  	Attn: Head of Licensing, Litigation & Trademarks
		  	Facsimile:	  	+45 4498 0670
		
	If to ZGEN:	  	ZymoGenetics, Inc.
		  	1201 Eastlake Avenue East
		  	Seattle, WA 98102
		  	Attn: Vice President, Law & Compliance
		  	Facsimile:	  	(206) 442-6697

 or to such other addresses as the
addressee may have specified in a notice duly given to the sender as provided herein. Such notices or other communication will be deemed effective as of the date so delivered (either personally or by courier service) or faxed. 
  

	12.10	Severability 

 The parties
agree that, if any provision of this Agreement shall for any reason be held to be invalid or unenforceable, such provision shall be enforced to the maximum extent permitted by law and the parties’ fundamental intentions hereunder, and the
remaining provisions hereof shall not be affected, impaired or invalidated and shall continue in full force and effect. 
  

	12.11	Headings 

 The headings
contained herein are for reference only and shall not be considered a part of this Agreement, nor shall they in any way affect the interpretation hereof. 
  

	12.12	Review of Agreement 

 This
Agreement has been submitted to the scrutiny of both parties and their counsel and shall be given a fair and reasonable interpretation in accordance with the words hereof, without consideration or weight being given to its being drafted by or for
one of the parties. 
  

 -42- 

	12.13	Compliance with Laws; Export Regulations 

 In performance of this Agreement, each party shall comply with all laws, regulations, rules, orders and other requirements and guidelines, now or hereafter in effect, and governmental authorities having
jurisdiction. This Agreement and any information related to IL-21 Related Know-How provided hereunder are subject to restrictions concerning the export of information and materials that may be imposed by government. Accordingly, NN agrees that it
will not export, directly or indirectly, any information or materials acquired under this Agreement or any products utilizing such information or materials to any country for which a government or any agency thereof at the time of export requires an
export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency of the government when required by an applicable statute or regulation. 
  

	12.14	[*] 

 Prior to executing
the USA Co-Promotion Agreement, the parties shall inform each other of their respective [*] (“[*]”), if any. Thereafter, the parties shall make suitable representatives reasonably available to discuss such [*]. 
  

	12.15	Counterparts 

 This
Agreement may be executed in two or more counterparts each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  

 -43- 
 * Confidential Treatment Requested. 

 IN WITNESS WHEREOF, the parties have executed and delivered this Agreement to be effective
as of the Effective Date. 
  

			
	NOVO NORDISK A/S
		
	By:	 	 /s/ JESPER BRANDGAARD

		 	Jesper Brandgaard
	Its:	 	Chief Financial Officer
		
	By:	 	 /s/ MADS KROGSGAARD THOMSEN

		 	Mads Krogsgaard Thomsen
	Its:	 	Chief Science Officer
	
	ZYMOGENETICS, INC.
		
	By:	 	 /s/ DOUGLAS E. WILLIAMS

		 	Douglas E. Williams, Ph.D.
	Its:	 	Chief Executive Officer

  

 -44- 

 [*] 
  

 Schedule 1 
 -1- 
 * Confidential Treatment Requested. 

 SCHEDULE 2 
 to the Third Restated License Agreement 
 for IL-21
Embodiments, 
 dated December 3, 2009 
 PRESS RELEASE 
 Novo Nordisk licenses IL-21 mAb and
patent rights to IL-21 antibodies from 
 ZymoGenetics 
 24 million US dollars upfront payment with 157.5 million dollars of total potential 
 milestone payments 
 Seattle, [month, day], 2009—
Novo Nordisk A/S (NYSE: NVO) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today announced an agreement where Novo Nordisk in-licenses a fully-human anti-IL21 monoclonal antibody (IL-21 mAb) developed by ZymoGenetics, as well as broad intellectual property
rights covering IL-21 mAb and the development of other IL-21 antibodies. The IL-21 mAb is a pre-IND candidate for the treatment of autoimmune and inflammatory diseases. Novo Nordisk in-licensed intellectual property rights to IL-21 antibodies
outside North America in 2001 and now has worldwide rights. 
 Under the terms of the licence, Novo Nordisk has agreed to pay
ZymoGenetics an initial upfront cash payment of 24 million dollars. In addition, as the development programme of the IL-21 mAb advances, ZymoGenetics may receive further milestones from Novo Nordisk of up to 157.5 million dollars over the
term of the agreement, including a 1.5 million dollar milestone payment upon filing an investigational new drug application and a 8.5 million dollar milestone payment at the start of phase 1 studies with the mAb, plus royalties on net
sales. ZymoGenetics also has a right to co-promote the IL-21 mAb product in the US if the company contributes to phase 3 clinical development costs. 
 “Novo Nordisk is currently building a pipeline of products to treat autoimmune and inflammatory diseases such as rheumatoid arthritis, lupus and inflammatory bowel disease,” said Mads Krogsgaard
Thomsen, executive vice president and chief science officer of Novo Nordisk. “It was important for us to secure the worldwide rights to the IL-21 mAb project as well as worldwide patent rights to IL-21 antibodies, and we look forward to
initiating a phase 1 trial with this IL-21 mAb in 2010.” 
 “ZymoGenetics has a rich pipeline and, while the IL-21 mAb
is an exciting molecule, we believe that other development programmes offer us a better opportunity for return on investment,” said Douglas E Williams, PhD, chief executive officer of ZymoGenetics. “We believe that Novo Nordisk will be
able to develop and create value for this asset. Furthermore, we have the option to increase our participation in commercialisation of the product, retaining long-term upside potential for our shareholders.” 
  

 Schedule 2 
 -1- 

 As part of the agreement, ZymoGenetics retains the option to fund a portion of phase 3
clinical development costs in exchange for an increased royalty rate on US sales and US co-promotion rights. If ZymoGenetics exercises the option, it would pay a fixed fee of 10 million dollars together with 15% of the costs of phase 3 clinical
trials, and royalties on US sales would increase from single to double digits. 
 IL-21 mAb 
 ZymoGenetics developed a fully-human anti-IL-21 monoclonal antibody, or IL-21 mAb, as a potential therapeutic treatment for autoimmune and
chronic inflammatory disorders. Cell biology experiments and preclinical models of inflammatory diseases suggest that IL-21 is a key mediator of inflammation, and over-expression patterns of IL-21 and its receptor in inflamed tissues of human
diseases, such as in inflammatory bowel disease, rheumatoid arthritis and lupus, further support the role of IL-21 in the disease process. 
 ZymoGenetics is focused on the creation of novel protein drugs to improve patient care and address unmet medical needs. The company’s strategy is to discover, develop and
commercialize its products independently, in collaboration with partner companies or through out-licensing. ZymoGenetics developed and markets RECOTHROM® Thrombin, topical (Recombinant). The company is developing a proprietary portfolio of immune-based product candidates. PEG-Interferon lambda is a novel type-3
interferon in clinical development for the treatment of chronic hepatitis C infection. Interleukin-21 is a novel cytokine in clinical development for the treatment of metastatic melanoma and renal cell carcinoma. Several other proprietary product
candidates are in preclinical development. In addition, ZymoGenetics has licensed rights to multiple clinical and preclinical drug candidates being developed by other companies. For further information, visit www.zymogenetics.com.

 Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading
position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical
profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and
London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com. 
 ZymoGenetics Forward-Looking Statements 
 This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future performance and
involve risks and uncertainties that are difficult to predict. ZymoGenetics actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated
with ZymoGenetics dependence on Novo Nordisk to develop and commercialize IL-21 mAb. In particular, ZymoGenetics ability to generate revenues from the license arrangement is subject to numerous risks, including, among other things: the possibility
that Novo Nordisk chooses to scale back or discontinue its development of IL-21 mAb due to, among other things, changes in its strategies, restructuring, mergers or acquisitions; the

  

 Schedule 2 
 -2- 

 
possibility that clinical trials involving IL-21 mAb reveal that it is not effective or has undesirable side effects, unacceptable toxicities or other characteristics that preclude regulatory
approval or prevent or limit commercial use; and the length of time that it takes for Novo Nordisk to solve technical problems or achieve various clinical development and regulatory approval milestones. In addition, the forward-looking statements in
this press release are subject to the other risks detailed in the other risks detailed in the ZymoGenetics Annual Report on Form 10-K for the year ended December 31, 2008, Quarterly Report on Form 10-Q for the quarter ended June 30, 2009
and from time to time in other reports filed by ZymoGenetics with the U.S. Securities and Exchange Commission. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release,
whether as a result of new information, future events or otherwise. 
  

			
	 Further information:
	  	
		
	Novo Nordisk Media:	  	Novo Nordisk Investors:
		
	Rachel Curtis Gravesen	  	Mads Veggerby Lausten
	Tel: (+45) 4442 7603	  	Tel: (+45) 4443 7919
	rcgv@novonordisk.com	  	mlau@novonordisk.com
		
		  	Kasper Roseeuw Poulsen
		  	Tel: (+45) 4442 4471
		  	krop@novonordisk.com
		
	In North America:	  	In North America:
	Sean Clements	  	Hans Rommer
	Tel: (+1) 609 514 8316	  	Tel: (+1) 609 919 7937
	secl@novonordisk.com	  	hrmm@novonordisk.com

 ZymoGenetics Media and Investors: 
 Susan W Specht 206-442-6592 
  

 Schedule 2 
 -3- 

 [*] 
  

 Schedule 3 
 -1- 
 * Confidential Treatment Requested. 

 [*] 
  

 Appendix 1 
 -1- 
 * Confidential Treatment Requested. 

 [*] 
  

 Appendix 2 
 -1- 
 * Confidential Treatment Requested. 

 [*] 
  

 Appendix 3 
 -1- 
 * Confidential Treatment Requested. 

 [*] 
  

 Schedule 1 to Appendix 3 
 -1- 
 * Confidential Treatment Requested. 

 APPENDIX 4 
 to the Third Restated License Agreement 
 for IL-21
Embodiments, 
 dated December 3, 2009 
 NOVO NORDISK INVOICE INSTRUCTIONS 
 Novo Nordisk Invoice
Instructions 
 We kindly ask you to comply with the following guidelines when sending invoices to NN. A properly formulated invoice is a
requirement for payment by NN. 
 Invoices must be addressed to the address directly below and may be sent to NN as a PDF file attached to an
email at [*] 
 [*] 
 Alternatively, hard copy invoices may be sent by mail or courier to the address above. 
 NN does not accept invoices received
via facsimile. 
 All invoices must include: 
  

	 	•	 	 A clear statement that the document sent is an invoice 

  

	 	•	 	 A reference to the NN agreement ID 

  

	 	•	 	 A reference to the specific section in the contract that identifies the payment obligation Value Added Tax number or Federal ID/registration number of
your affiliation (if relevant) 

  

	 	•	 	 Recipient’s bank information that uniquely identifies recipient’s bank account: 

 1. International Bank Account Number and/or IBAN code (the latter is applicable in all EU countries): [*] 
 2. Name of Bank: [*] 
 3. Address of Bank: [*] 
 4. Bank details (e.g. ACH/ABA/Routing/Fedwire/Transit number/Sort Number):[*]

  

 Appendix 4 
 -1- 
 * Confidential Treatment Requested. 

 5. Swift code: [*] 
 6. Account Name: [*] 
 7. Currency: [*] 
 If you have questions regarding the above, please contact the person identified above as being your NN contact
person. 
 Thank you very much for your cooperation. 
  

 Appendix 4 
 -2- 
 * Confidential Treatment Requested. 

 [*] 
  

 Appendix 5 
 -1- 
 * Confidential Treatment Requested. 

 [*] 
  

 Appendix 6 
 -1- 
 * Confidential Treatment Requested.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]